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Background: Venous leg ulcers (VLUs) are the most common cause of leg ulceration, affecting 1 in
100 adults. VLUs may take many months to heal (25% fail to heal). Estimated prevalence is between
1% and 3% of the elderly population. Compression is the mainstay of treatment and few additional
therapies exist to improve healing. Two previous trials have indicated that low-dose aspirin, as an adjunct
to standard care, may improve healing time, but these trials were insufficiently robust. Aspirin is an
inexpensive, widely used medication but its safety and efficacy in the treatment of VLUs remains to
be established.
Objectives: Primary objective – to assess the effects of 300 mg of aspirin (daily) versus placebo on the
time to healing of the reference VLU. Secondary objectives – to assess the feasibility of leading into a
larger pragmatic Phase III trial and the safety of aspirin in this population.
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Design: A multicentred, pilot, Phase II randomised double-blind, parallel-group, placebo-controlled
efficacy trial.
Setting: Community leg ulcer clinics or services, hospital outpatient clinics, leg ulcer clinics, tissue viability
clinics and wound clinics in England, Wales and Scotland.
Participants: Patients aged ≥ 18 years with a chronic VLU (i.e. the VLU is > 6 weeks in duration or the
patient has a history of VLU) and who are not regularly taking aspirin.
Interventions: 300 mg of daily oral aspirin versus placebo. All patients were offered care in accordance
with Scottish Intercollegiate Guidelines Network (SIGN) guidance with multicomponent compression
therapy aiming to deliver 40 mmHg at the ankle when possible.
Randomisation: Participants were allocated in a 1 : 1 (aspirin : placebo) ratio by the Research Pharmacy,
St George’s University Hospitals NHS Foundation Trust, using a randomisation schedule generated in
advance by the investigational medicinal product manufacturer. Randomisation was stratified according to
ulcer size (≤ 5cm2 or > 5cm2).
Main outcome measure: The primary outcome was time to healing of the largest eligible ulcer
(reference ulcer).
Feasibility results – recruitment: 27 patients were recruited from eight sites over a period of 8 months.
The target of 100 patients was not achieved and two sites did not recruit. Barriers to recruitment included
a short recruitment window and a large proportion of participants failing to meet the eligibility criteria.
Results: The average age of the 27 randomised participants (placebo, n = 13; aspirin, n = 14) was 62 years
(standard deviation 13 years), and two-thirds were male (n = 18). Participants had their reference ulcer for
a median of 15 months, and the median size of ulcer was 17.1 cm2. There was no evidence of a difference
in time to healing of the reference ulcer between groups in an adjusted analysis for log-ulcer area and
duration (hazard ratio 0.58, 95% confidence interval 0.18 to 1.85; p = 0.357). One expected, related
serious adverse event was recorded for a participant in the aspirin group.
Limitations: The trial under-recruited because many patients did not meet the eligibility criteria.
Conclusions: There was no evidence that aspirin was efficacious in hastening the healing of chronic VLUs.
It can be concluded that a larger Phase III (effectiveness) trial would not be feasible.
Trial registration: Clinical Trials.gov NCT02333123; European Clinical Trials Database (EudraCT)
2014-003979-39.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 55.
See the NIHR Journals Library website for further project information.
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Plain English summary
We conducted a small randomised controlled trial to look at whether or not a daily dose of 300 mg ofaspirin may help to heal venous leg ulcers. The aim of the trial was also to enable a decision to be
made about whether or not a large trial should be undertaken to confirm our results. We also looked at
whether or not aspirin is safe to use in people with leg ulcers. We aimed to recruit 100 patients from leg
ulcer clinics. Half of the patients recruited received 300-mg capsules of aspirin and the other half received
a dummy drug (placebo). Both groups also received the usual ulcer treatment of compression therapy
and dressings. Participants and doctors were unaware whether an individual had received aspirin or the
dummy drug.
We measured how long it took the largest ulcer to heal as the main measure of treatment success. We
also measured changes in the size of participants’ reference (largest eligible) ulcer over 6 months using
photographs and tracings of the wound outline, and collected information about the amount of pain
caused by the ulcer, how often participants took the study drug and the number of visits participants had
to the hospital or their general practitioner.
We concluded that a larger trial recruiting the same type of patients would not be possible as we recruited
only 27 participants instead of the 100 participants that we were aiming for. The main reasons that we
could not recruit more patients in the time available were that many patients were already taking aspirin
and/or their ulcer was smaller than the ulcer size we were investigating. Aspirin appears to be safe in this
population; however, because we only recruited a small number of participants, we were unable to
confirm if it might be effective for healing leg ulcers.
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Scientific summary
Background
Venous leg ulcers (VLUs) are wounds of the lower limb caused by disease of the venous system that
result in chronically swollen legs and damage to the tissues, usually around the ankles. Chronic ulcers are
those present for ≥ 6 weeks or those that are recurrent. VLUs may take many months to heal and 25%
fail to heal. Estimated prevalence of VLUs is between 1% and 3% of the elderly population. At present,
compression is the mainstay of treatment for VLU and few additional therapies exist to improve healing.
This has been shown to be effective in many clinical trials. However, despite this treatment, patients take
many months to heal (with median healing times of approximately 12 weeks in previous trials) and,
for some patients, compression therapy does not result in resolution of their leg ulcers.
Objectives
The objectives were to assess the efficacy of aspirin for time to healing of chronic VLUs, to examine the
safety of this aspirin intervention in this cohort of patients and to inform the feasibility of study procedures,
such as recruitment, in order to proceed from a Phase II trial to a Phase III randomised controlled trial of
clinical effectiveness and cost-effectiveness.
Primary objective
To compare the effects of 300 mg of aspirin plus standard care with placebo plus standard care on time to
healing of the reference chronic VLU (largest eligible venous ulcer).
Secondary objectives
To assess the safety of aspirin in patients with VLUs and feasibility of leading directly from the pilot Phase II
trial into a larger pragmatic study (Phase III) of effectiveness and efficiency, and check, in accordance with
the Acceptance Checklist for Clinical Effectiveness Pilot Trials (ACCEPT) criteria, whether or not the pilot
study fulfilled four criteria:
1. confirming that the effect sizes in the British and Spanish RCTs were too large, but
2. confirming that smaller effect sizes were still plausible, while
3. confirming that the intervention does not lead to unacceptably high rates of serious adverse events
(SAEs), and
4. confirming that we can recruit at the planned rate.
Design
The Aspirin for Venous leg Ulcers Randomised Trial (AVURT) was a multicentred, pilot, Phase II randomised
double blind, parallel-group, placebo-controlled efficacy trial. Participants were randomised to receive
300 mg of aspirin or placebo in a 1 : 1 ratio.
Setting
Participants were recruited from 10 centres in England, Wales and Scotland that were treating leg ulcers.
Centres were recruited throughout the trial.
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Participants
Inclusion criteria
To be eligible for the study, it was necessary for participants to meet all of the following criteria.
l Having at least one chronic VLU, that is, the VLU has (1) been present for > 6 weeks or (2) occurred in a
person with a history of venous leg ulceration. Ulcers were considered purely venous if clinically no other
aetiology was suspected. The ulcer was required to be venous in appearance (i.e. moist, shallow, of an
irregular shape) and lie wholly or partially within the gaiter region of the leg. If the patient had more
than one ulcer, then we chose the largest ulcer as the reference ulcer for purposes of the analysis.
l Having an ulcer with an area of > 1 cm2.
l Having had an ankle–brachial pressure index (ABPI) of ≥ 0.8 taken within the previous 3 months or,
when the ABPI is incompressible, other accepted forms of assessment included peripheral pulse
examination/toe pressure/Duplex ultrasonography in combination with clinical judgement to be used
to exclude peripheral arterial disease.
l Being aged ≥ 18 years (there was no upper age limit).
l Being able to provide informed consent.
Exclusion criteria
Potential participants were excluded if they fulfilled any of the following criteria.
l Being unable or unwilling to provide consent.
l Having a foot (below the ankle) ulcer.
l Having a leg ulcer of non-venous aetiology (i.e. arterial).
l Having an ABPI of < 0.8.
l Using (self-administered or prescribed) regular concomitant aspirin.
l Having a previous intolerance of aspirin/contraindication to aspirin (decision made according to the
prescribers’ clinical judgement).
l Taking contraindicated medication: probenecid, oral anticoagulants including coumarins [warfarin and
acenocoumarol (Sinthrome®, Merus Labs Luxco S.a.R.L., Amsterdam, the Netherlands)] and phenindione
(Dindevan®, Concordia International Corp., Oakville, ON, Canada), dabigatran (Pradaxa®, Boehringer
Ingelheim Limited, Bracknell, UK), rivaroxaban (Xarelto®, Bayer AG, Leverkusen, Germany), apixiban
(Eliquis®, Bristol-Myers Squibb, New York, NY, USA), heparin, clopidogrel, dipyridamole, sulfinpyrazone
and iloprost.
l Having known lactose intolerance.
l Being a pregnant or lactating/breastfeeding woman.
l Being male or a pre-menopausal female of child-bearing potential unwilling to use an effective method
of birth control.
l Currently participating in another study evaluating leg ulcer therapies.
l Having another reason that excluded them from participating within this trial (decision made according
to the nurses’ or prescribers’ clinical judgement).
l Having previously been recruited to this trial.
Patients were pre-screened on the basis of three criteria (concomitant aspirin, wound size and ulcer
duration or history of venous ulceration) by study research nurses to determine which patients might be
eligible for the study.
Interventions
A 300-mg dose of daily oral aspirin for 24 weeks (four × 75-mg tablets were encapsulated in size 00
capsules with added lactose and magnesium stearate blend as filler) and placebo (size 00 capsules with
lactose and magnesium stearate blend as filler, which were identical in weight, colour and size to the
aspirin capsules).
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All participants were offered an evidence-based standardised approach to the management of their leg
ulcers in accordance with Scottish Intercollegiate Guidelines Network (SIGN) guidance. This consisted of
multicomponent compression therapy aiming to deliver 40 mmHg of pressure at the ankle, when possible.
The type of dressing used was at the discretion of the health-care professionals managing the participants.
Randomisation
Recruiting sites contacted the Research Pharmacy (St George’s University Hospitals NHS Foundation Trust,
London, UK), which conducted the random allocation. Patients were randomly allocated in a 1 : 1 ratio to
either aspirin or placebo using a randomisation schedule generated by the investigational medicinal product
(IMP) manufacturer in advance. Randomisation was stratified according to ulcer size (≤ 5 cm2 or > 5 cm2), as
ulcer size is the strongest predictor of outcome. The randomisation identifier on the schedule corresponded
to IMP bottle number.
Participants, investigators, research and treating nurses and other attending clinicians were blind to treatment
throughout the trial. There was a 24-hour emergency code break facility at the Research Pharmacy.
Outcome measures
Outcome measures included time to healing of the reference ulcer (primary outcome), ulcer size, adverse
events (AEs), ulcer recurrence (following healing), ulcer-related pain measured using a visual analogue scale
(VAS), treatment compliance and resource use.
Methods
Outcome assessments were made by research nurses or treating nurses weekly or fortnightly for a
minimum of 25 weeks post randomisation.
Following the confirmation of a participant’s eligibility, and before randomisation, a baseline assessment
was conducted by the study or research nurse, including participant details and ulcer history assessment.
Digital photographs and tracings were taken, as was information on baseline ulcer-related pain.
Measurement of primary outcome
Healing was defined as complete epithelial cover in the absence of a scab (eschar) with no dressing
required. This was determined by the treating nurse or research nurse and a digital photograph was taken
of the wound area. After the ulcer was initially judged to be healed, participants were followed for a
further 2 weeks to confirm healing.
Measurement of secondary outcomes
The reference ulcer was measured using wound grid tracings at screening, baseline and at final follow-up
and at other follow-up visits when a photograph could not be taken.
Ulcer-related pain was collected at baseline and at weeks 4, 5 and 6 after randomisation using a 21-point
box scale.
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Participant concordance with treatment (IMP and compression) was recorded in the weekly case report
forms (CRFs) and at the end of the study with return of the empty container to the Research Pharmacy,
which undertook a pill count.
Resource use was recorded on CRFs, with change to type of changes of dressing/compression recorded as
well as the number of wound consultations.
At each follow-up appointment, treating nurses asked participants if they had experienced any SAEs,
AEs or adverse reactions and indicated the participant’s response (‘yes’ or ‘no’) in the CRFs.
Participants were deemed to have exited the trial when they withdrew consent, were lost to follow-up,
died or had completed follow-up.
Results
The original participant recruitment window was extended from 6 to 8 months owing to poor
patient recruitment.
The main reasons for participant ineligibility were:
l already taking aspirin or other prohibited medication
l having a small or otherwise ineligible ulcer.
Modifying the eligibility criteria to improve recruitment was not possible except for adopting a smaller
wound size. However, this was rejected as ulcers with a wound area of < 1 cm2 usually heal very rapidly.
There were external factors outside the control of the research team that meant that sites were slow to
open. A range of options were considered and explored to improve recruitment, including recruitment
from primary care. Preliminary searches of records in primary care also indicated very few potentially
eligible participants. In addition, the trial’s short recruitment window and budget constraints meant that
many of the options considered were not viable without a funded extension.
Analyses were conducted following the principles of intention to treat with all events analysed
according to the participant’s original treatment allocation. Pre-screening was under-reported as the
first pre-screening log was not completed by some sites. The number of patients for whom we had
pre-screening data was 457 and the number of participants who consented was 29. Two patients were
excluded after consent was given and before randomisation.
The average age of the 27 randomised participants was 62 years [standard deviation (SD) 13 years], and
two-thirds were male (n = 18). Participants had had their reference ulcer for a median of 15 months
and the median size of ulcer was 17.1 cm2.
There was one withdrawal during the course of the study (placebo), for whom data on primary outcome
were not possible to obtain. This was reported at week 2 and so no follow-up data are available for this
patient beyond week 1. The other four patients (placebo, n = 2; aspirin, n = 2) either agreed to withdraw
from treatment but provided full follow-up until week 25 or healed at a point before withdrawal and,
thus, all four provided primary outcome data.
Overall, 13 out of the 26 participants (50.0%) who were followed up were recorded as healing during the
course of the study. All the reference ulcers reported to be healed on a CRF were confirmed healed
approximately 2 weeks later. Seven out of 12 participants (58.3%) followed up in the placebo group and
6 out of 14 (42.9%) in the aspirin group were observed to have a healed reference ulcer. It was not possible
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to estimate median time to healing and/or corresponding 95% confidence intervals (CIs) because less than,
or close to, half of the patients were observed to have healed during the follow-up period of the study.
The primary analysis investigated the difference in time to healing by trial arm. Hazard ratios (HRs) and
corresponding 95% CIs were obtained from a Cox regression model adjusted for ulcer area and ulcer
duration at baseline (both logarithmically transformed): the HR of aspirin versus placebo (allocation) was
0.58 (95% CI 0.18 to 1.85; p = 0.36). Overall, these data do not provide evidence of a difference in time
to healing with the addition of aspirin to usual care. The numbers within this feasibility study are small and
results are inconclusive in terms of the primary outcome.
Secondary outcomes
Adverse events
Six out of the 26 (23.1%) participants who were followed up had no reported AEs (placebo, n = 3;
aspirin, n = 3) and the remaining 20 had AEs (placebo, n = 9; aspirin, n = 11). The total number of events
experienced by participants was compared by trial arm, adjusting for the prognostic factors (log of baseline
reference ulcer area and log of baseline reference ulcer duration) using negative binomial regression as per
the statistical analysis plan. There was no evidence that participants receiving aspirin were more likely to
suffer an AE than those receiving placebo (incidence rate ratio 1.31, 95% CI 0.51 to 3.41; p = 0.58).
One participant suffered one SAE during the course of the study, requiring a blood transfusion for
gastrointestinal bleeding. There were 88 non-serious AEs (placebo, n = 36; aspirin, n = 52) recorded in
total among 20 participants (placebo, n = 9; aspirin, n = 11). The majority of these were not related to
the IMP.
The mean baseline VAS score for ulcer-related pain was 37.7 (95% CI 22.0 to 53.4) in the placebo group
and 45.4 (95% CI 24.6 to 66.2) in the aspirin group; the mean VAS score at week 5 was 13.3 (95% CI
0.3 to 26.3) in the placebo group and 28.5 (95% CI 10.6 to 46.3) in the aspirin group.
Of the 13 participants who healed, 12 were assessed for ulcer recurrence using the recurrence assessment
form. Recurrence was reported for two patients (placebo, n = 1; aspirin, n = 1).
Participants took their first dose of study drug a median of 4 days after randomisation (range 1–12 days)
and the majority took their first dose in the morning (70.8%; placebo, n = 9; aspirin, n = 8).
Compliance
The mean number of visits attended up until healing or study exit was 13.3 (SD 7.3) and 17.4 (SD 6.8) in
the placebo and aspirin groups, respectively. Ten out of the 12 participants (83.3%) in the placebo group
and 10 out of the 14 participants (71.4%) in the aspirin group were fully compliant with their compression
therapy. Two participants in the placebo group (16.7%) and four participants in the aspirin group (23.1%)
were partially compliant.
Eight out of the 12 participants (66.7%) in the placebo group were deemed fully compliant with taking
the study medication while four (33.3%) were partially compliant. In the aspirin group, 11 out of the
14 participants (78.6%) were deemed fully compliant and three (21.4%) were partially compliant.
All participants in the placebo group were prescribed high-level compression therapy (≥ 40 mmHg) at
baseline and, of those in the aspirin group, 12 were prescribed high-level compression therapy and two
medium-level compression therapy (20–39 mmHg).
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The total number of changes to the compression therapy prescribed at baseline during the study was 16,
with five changes (31.3%) to a medium-compression level, nine changes (56.3%) to a high-compression
level, one change (6.2%) to a low-compression level and one change (6.2%) to no compression at all.
The mean number of wound consultations per week was 2.1 (SD 1.4) in the placebo group, 1.9 (SD 0.7)
in the aspirin group and 2.0 (SD 1.0) overall.
One participant was unblinded after the trial had completed and analysis was being undertaken, in
accordance with the emergency unblinding procedure. There were no protocol violations.
Conclusions
AVURT was a Phase II randomised pilot trial of aspirin versus placebo for the treatment of patients with
chronic venous leg ulceration. It was not possible to recruit the planned number of patients despite an
unfunded extension to the trial and, therefore, it can be concluded that a larger Phase III (effectiveness)
trial would not be feasible.
Trial registration
This trial is registered as Clinical Trials.gov NCT02333123 and European Clinical Trials Database (EudraCT)
2014-003979-39.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Chronic venous leg ulcers
Chronic venous leg ulcers (VLUs) are wounds of the lower limb caused by a diseased venous system, which
results in swollen legs and damage to the tissues, usually around the ankles. VLUs are most commonly the
result of severe varicose veins, a previous deep-vein thrombosis, trauma or failure of the calf muscle pump,
all of which result in impaired venous return. Obesity and immobility are additional important factors
contributing to venous dysfunction.1
The VLUs may take many months to heal (with approximately 25% failing to heal completely), during which
time they result in significant suffering and reduction in quality of life for patients.2 VLUs have a tendency
to become recurrent, with rates of recurrence estimated at between 18% and 28%.3 As a result, the
management of VLUs represents a substantial cost to the NHS, the majority of which is attributed to nurse
time. Estimated lifetime prevalence of VLUs is between 1% and 3% of the elderly population in the USA and
Europe.4 It is estimated that 1% of the adult population will suffer from leg ulcers at some point in their life.5
Furthermore, incidence and prevalence of ulceration is predicted to increase as a result of the increasing age
and obesity of the population in the USA and Europe. A recent cohort study conducted in the UK estimated
that 278,000 VLUs per year are managed by the NHS.6 Furthermore, the annual cost to the NHS of this
management was estimated to be £941M, with substantially more cost associated with unhealed wounds.7
Current treatment strategies
Current treatment strategies for VLUs focus on efforts to reduce venous hypertension. At present,
compression is the main treatment for venous ulceration and few additional therapies have robust
evidence to suggest they improve healing rates.
Compression therapy
The mainstay of treatment of leg ulcers is graded compression therapy (target pressure of 40 mmHg) and
this is the recommended first-line treatment in UK guidelines.2 The aim of compression therapy is the
reduction of venous hypertension, improvement in calf muscle function and the creation of a wound
environment conducive to wound healing. Compression therapy in the form of bandages and hosiery has
been shown to be effective in many randomised controlled trials (RCTs).8 However, despite this treatment,
patients take many months to heal (with median healing times of approximately 12 weeks in previous
trials)3 and for some patients compression therapy does not result in resolution of their leg ulcers. The use
of compression (as well as dressings, largely to manage the wound exudate) can be expensive as nurse
time is required to change bandages, which can be required weekly or more frequently.
In addition, effective treatment of VLU requires adherence to compression therapy which, for many
patients, is uncomfortable and sometimes painful and inconvenient for everyday life (compression is bulky
and dressings have to be changed several times weekly). In addition, the use of thicker bandaging systems,
such as four-layer bandaging, may restrict movement of the ankle and cause difficulty in wearing shoes.9
Topical therapies
The most frequently used topical antimicrobials in wound care practice are chlorhexidine, iodine, silver-
containing products, mupriocin (Bactroban®, GlaxoSmithKline, Brentford, UK) and fucidic acid. Historically,
agents such as acetic acid, honey, hydrogen peroxide, sodium hypochlorite, potassium permanganate and
proflavine have all been used.10 There is currently a lack of reliable evidence to support an association
between topical agents and reduction in time to healing in VLUs.11
DOI: 10.3310/hta22550 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 55
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Tilbrook et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Adjunctive drug therapies
A recent Cochrane review has shown pentoxifylline to be an effective adjunct to compression therapy
and possibly more effective than placebo or no treatment in the absence of compression.12 However,
pentoxifylline is not commonly prescribed in the NHS13 and has common and intolerable side effects,
some of which have the potential to be life-threatening.14 Other adjunctive drugs, including venoactive
drugs, are not recommended owing to insufficient evidence regarding their use and unclear mechanism
of action.15
Surgery
Surgery to treat superficial varicose veins has been shown to prevent recurrence of ulcers once they have
healed but does not improve time to healing of existing ulcers.16 An ongoing RCT is further investigating
surgery as a treatment for chronic ulceration, comparing early versus delayed endovenous treatment of
superficial venous reflux.17 This study is due to publish in November 2018.17
Other therapies
Research into the use of novel cell-based therapies, such as allogenic cells and growth factors, is currently
in progress.18–20 Owing to their cost and associated side effects, it is thought that such therapies are
unlikely to be made widely available.18 If other treatments were able to reduce the time to healing, this
would be a significant breakthrough.
Potential role of aspirin as a treatment for venous leg ulcers
Aspirin (also known as acetylsalicylic acid) has been widely used as a medication for > 100 years and
is inexpensive, readily available and generally safe to use. Aspirin is a cyclo-oxygenase inhibitor that
irreversibly reduces prostaglandin 2 and thromboxane A2.21 At low doses, it is used very widely to reduce
cardiovascular events in those at high risk.22
The exact mechanism by which aspirin may improve time to healing of VLUs is unclear but it is potentially
associated with both the inhibition of platelet activation and the reduction of inflammation.23
Possible adverse events (AEs) associated with the use of aspirin include gastric ulceration and other
gastrointestinal effects. Other effects include liver and renal toxicity, exacerbation of asthma and
dermatological reactions. Antiplatelet drugs, when administered in combination with anticoagulants,
are associated with a higher risk of gastrointestinal bleeding than that associated with each drug class
used alone.24
Existing evidence on aspirin in the treatment of venous leg ulcers
To date, there have been two small RCTs that have investigated the use of aspirin (300mg/day) in patients
with VLUs of ≥ 2 cm2 in area. The first, a UK-based study in 20 participants, reported healing of 38% of
ulcers in the intervention group (aspirin in combination with compression therapy), compared with 0%
in the control group (placebo in combination with compression therapy), over a study period of 4 months.
The average time to healing was not reported.25 del Río Solá et al.26 reported a study of 51 participants to
whom aspirin was given in combination with compression therapy (n = 23) compared with compression
therapy alone (n = 28). The researchers reported the average time to healing as 12 weeks in the aspirin group
compared with 22 weeks in the control group, but that there was no significant difference between groups in
the proportion of patients with ulcers healed (74% in the aspirin group and 75% in the control group). These
two studies were the only RCTs identified in a recently conducted Cochrane systematic review23 and, owing to
variations and limitations in the data, a meta-analysis was not undertaken. Application of GRADE (Grading of
Recommendations, Assessment, Development and Evaluations)27 to the data highlighted that the evidence
was of low to very low quality.
BACKGROUND
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Explanation of rationale
The Aspirin for Venous leg Ulcers Randomised Trial (AVURT) was undertaken to address the primary
question of whether or not the addition of 300 mg of daily aspirin to standard evidence-based therapies
demonstrates evidence of a reduction in time to healing of VLUs. This pilot trial was developed to explore
this question as well as assessing the feasibility (especially in terms of participant recruitment and
treatment compliance) and safety (in terms of aspirin-related AEs) of conducting a larger-scale pragmatic
study, powered to investigate the clinical effectiveness and cost-effectiveness of aspirin for VLU healing.
This research is important because leg ulcers are common and costly and result in significant patient
suffering.2 If aspirin, which is commonly used in many patients, was able to reduce the time to healing of
VLU with limited risk of treatment-related harm, then this would result in a potentially important reduction
in resource use and an improvement in patients’ health-related quality of life. Because aspirin is generally
safe, cheap, well tolerated (for most patients) and widely available, the potential impact on this population
is large.
Two previously conducted RCTs have been performed on the use of aspirin in the treatment of VLUs.25,26
The findings of both trials suggested that there may be benefit in patients with VLUs taking aspirin:
one reported that a greater proportion of patients healed with 300 mg of aspirin together with standard
compression bandaging25 and one reported a shorter time to healing with 300 mg of aspirin in conjunction
with gradual compression therapy.26 However, both trials have been assessed as being at a risk of bias.23
The authors of the Cochrane review23 concluded that the low-quality and insufficient evidence from the
two included trials meant that they were unable to make definitive claims on the benefits and potential
harm of oral aspirin, as an adjunct to compression therapy, on the recurrence and healing of VLUs.
The Cochrane review23 recommended that further high-quality studies were needed.
A RCT is required to assess the potential effectiveness and safety profile of aspirin in this population.
However, it would be premature to conduct a full trial initially, not least as it is not clear how many people
with VLUs currently take aspirin or other antiplatelet medications and the potential impact of this on the
design and feasibility of any future study.
During the registration of AVURT, we identified two other RCTs investigating aspirin for VLUs. ASPiVLU
(ASPirin in Venous Leg Ulcer Healing)28 was a trial being conducted in Australia that was planning to
randomise patients with VLU to receive either 300 mg of aspirin or placebo. The primary end point of
that study was time to complete healing of reference ulcer at or before 12 weeks post randomisation.
Aspirin4VLU (Low Dose Aspirin for Venous Leg Ulcers) was a trial being conducted in New Zealand that
was planning to randomise VLU patients to either 150 mg of aspirin or placebo in addition to standard
care. The primary end point was time to complete healing of reference/largest ulcer. A secondary outcome
of this study is change in estimated reference ulcer area from baseline to 24 weeks.29
Research objectives
To assess the efficacy of aspirin on time to healing of VLUs, to examine safety issues in this cohort of
patients and to assess the feasibility of proceeding from a Phase II trial to a Phase III trial of clinical
effectiveness and cost-effectiveness.
Primary objective
To compare the effects of 300 mg of aspirin plus standard care with placebo plus standard care on time to
healing of the reference chronic VLU (largest eligible venous ulcer).
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Secondary objectives
To assess the safety of aspirin in patients with VLUs and feasibility of leading directly from the pilot Phase II
trial into a larger pragmatic study (Phase III) of effectiveness and efficiency, and check, in accordance with
the Acceptance Checklist for Clinical Effectiveness Pilot Trials (ACCEPT) criteria,30 whether or not the pilot
study fulfilled four criteria:
1. confirming that the effect sizes in the British and Spanish RCTs were too large, but
2. confirming that smaller effect sizes were still plausible, while
3. confirming that the intervention does not lead to unacceptably high rates of serious adverse events
(SAEs), and
4. confirming that we can recruit at the planned rate.
Additional objective
To perform an individual patient-level meta-analysis using the data from AVURT and other published25,26,31
and unpublished studies [e.g. A Carolina Weller Barker, I Darby, T Haines, M Underwood, S Ward, P Aldons,
E Dapiran, JJ Madan, P Loveland, A Sinha, M Vicaretti, R Wolfe, M Woodward, J McNeiJ (ASPiVLU). School
of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia, 2015]. The
objective of performing this meta-analysis is to assess the clinical effectiveness on time to healing of VLUs
and safety of aspirin use. This will take place following completion of the other trials, which are still
recruiting patients28,29 at the time of writing.
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Chapter 2 Methods
This chapter reports the methods used to conduct AVURT. It describes the study design and protocolfrom recruitment of participants to completion in the study, data analysis procedures, quality assurance
and governance. The trial protocol has been published.32
Design
A multicentred, pilot, Phase II randomised double-blind, parallel-group, placebo-controlled efficacy trial.
Setting
Patients presenting at community leg ulcer clinics/hospital outpatients’ clinics, or registered with a
leg ulcer clinic but receiving care at home, were recruited. Some sites could use patient identification
centres (PICs) to identify patients to take part. Participants were recruited from 10 centres in England,
Wales and Scotland (see Appendix 1) from leg ulcer hospital outpatient clinics (n = 5), community leg ulcer
clinics or community caseloads (n = 3), a wounds clinic in a university (n = 1) and a primary care leg ulcer
clinic (n = 1). At each of the nurse-led community centres (n = 3), a doctor was identified to work with the
centre to review and confirm the patient’s eligibility for the trial, to prescribe the investigational medicinal
product (IMP) and to review changes to concomitant medication.
Participants
Participant eligibility for the trial was assessed according to the criteria below.
Inclusion criteria
To be eligible for the study, it was necessary for participants to meet all of the following criteria.
l Having at least one chronic VLU, when chronic venous leg ulceration was defined as any break in the
skin that had either (1) been present for > 6 weeks or (2) occurred in a person with a history of venous
leg ulceration. Ulcers were considered purely venous if clinically no other aetiology was suspected.
The ulcer was required to be venous in appearance (i.e. moist, shallow, of an irregular shape) and lie
wholly or partially within the gaiter region of the leg. If the patient had more than one ulcer we chose
the largest as the ‘index’ or reference ulcer for purposes of the analysis.
l Having an ulcer with an area of > 1 cm2.
l Having had an ankle–brachial pressure index (ABPI) of ≥ 0.8 taken within the previous 3 months or,
when the ABPI is incompressible, other accepted forms of assessment included peripheral pulse
examination/toe pressure/Duplex ultrasonography in combination with clinical judgement to be used to
exclude peripheral arterial disease (PAD).
l Being aged ≥ 18 years (there was no upper age limit).
l Being able and willing to give informed consent.
Exclusion criteria
Potential participants were excluded if they fulfilled any of the following criteria.
l Being unable or unwilling to provide consent.
l Having a foot (below the ankle) ulcer.
l Having a leg ulcer of non-venous aetiology (i.e. arterial).
l Having an ABPI of < 0.8.
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l Using (self-administered or prescribed) regular concomitant aspirin.
l Having a previous intolerance of aspirin/contraindication to aspirin (decision made according to the
prescribers’ clinical judgement).
l Taking contraindicated medication: probenecid, oral anticoagulants including coumarins (warfarin and
acenocoumarol) and phenindione, dabigatran, rivaroxaban, apixiban, heparin, clopidogrel, dipyridamole,
sulfinpyrazone and iloprost.
l Having known lactose intolerance.
l Being a pregnant or lactating/breastfeeding woman.
l Being male or a pre-menopausal female of child-bearing potential unwilling to use an effective method
of birth control [i.e. either hormonal in the form of the contraceptive pill; barrier method of birth
control accompanied by the use of a proprietary spermicidal foam/gel or film; or agreement of true
abstinence (withdrawal, calendar, ovulation, symptothermal and post ovulation were not acceptable
methods)] from the time consent was signed until 6 weeks after the last dose of IMP. Participants were
only considered not of child-bearing potential if they were surgically sterile (i.e. they had undergone a
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they were postmenopausal.
l Currently participating in another study evaluating leg ulcer therapies.
l Having another reason that excluded them from participating within this trial (decision made according
to the nurses’ or prescribers’ clinical judgement).
l Having previously been recruited to this trial.
Recruitment
Patients were pre-screened on the basis of three criteria (concomitant aspirin, wound size and ulcer
duration or history of venous ulceration) by study research nurses to determine those potentially eligible
for the study. The reason(s) for ineligibility or not approaching patients were recorded on pre-screening
logs (see Appendix 2). Two pre-screening logs were issued. Completion of the first log (version 1.0) was
non-mandatory as stipulated by the trial sponsor (based on the sponsor’s belief that the clinics received a
heterogeneous referral pattern of mixed aetiology ulcers not thought to be truly representative of the
total population of patients with chronic VLUs). Following a recommendation by the Data Monitoring
Committee (DMC), the sponsor permitted a new pre-screening log that was made mandatory (version 2.0).
Patients attending clinics as part of their routine care and who satisfied the pre-screening criteria were
approached by study research nurses or designated health-care professionals and provided with both verbal
and written information about the trial in a face-to-face meeting (see Appendix 3). Patients were given a
minimum of 24 hours to consider participation in the trial. Study research nurses then obtained voluntary
full written consent from those patients who wanted to enter the trial (see Appendix 4). After they gave
consent, patients were screened against the study’s full eligibility criteria by the study research nurses or
designated health-care professionals using the screening case report form (CRF) (see Appendix 5). The
reason(s) for a patient’s ineligibility were recorded. Patients were informed that their eligibility would be
subject to confirmation by a medical practitioner and in all cases a medical practitioner determined and
confirmed patient eligibility following screening. If a potential participant was not known to the medical
practitioner, provision was made for the participant to be contacted by telephone by the medic to check for
any possible contraindications. When the medic was satisfied of patient eligibility, they would sign off the
prescription for the IMP (see Appendix 6).
Randomisation
Patients were randomly allocated in a 1 : 1 ratio to either aspirin or placebo by the Research Pharmacy
(St George’s University Hospitals NHS Foundation Trust, London, UK). Randomisation was stratified according
to ulcer size (≤ 5 cm2 or > 5 cm2) as this is the strongest known predictor of outcome.4
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Sequence generation
The aspirin and placebo manufacturer, Sharp Clinical Services (UK) Limited (registered office in Ashby-de-
la-zouch, UK), generated the randomisation schedule in advance. They provided one randomisation list
to the Research Pharmacy and a copy to the senior trial statistician in the York Trials Unit (YTU; University
of York). To facilitate participant allocation according to stratification, the allocation sequence on the
randomisation list was mirrored top to bottom bottom to top, and each allocation was referenced 1 to 120
for participant identifier (ID). Where the participant was placed on the randomisation list (top or bottom)
depended on the stratification of ulcer size (≤ 5 cm2 or > 5 cm2).
Allocation
After participant consent was taken and baseline data were recorded, the research site faxed the AVURT
prescription directly to the Research Pharmacy. The AVURT prescription also indicated ulcer size.
On receipt of the original signed prescription by post, the Research Pharmacy allocated the next available
randomisation ID. The randomisation ID corresponded to IMP bottle number for allocation (top or bottom),
in accordance with the ulcer size stratification as indicated on the prescription. IMP was dispensed by
St George’s and sent by courier under temperature-controlled conditions directly to all participants. The
date of randomisation, a unique patient ID and a unique screening ID were recorded by the Research
Pharmacy on a Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) spreadsheet, which was sent
to the YTU each week or when a participant was randomised.
Blinding
Participants, investigators, research and treating nurses and other attending clinicians were unaware of
the trial drug allocation throughout the trial. There was a 24-hour emergency code break facility at
the Research Pharmacy for health professionals to contact if they needed to determine whether or not
patients were receiving aspirin or placebo for onward clinical management. However, in practical terms,
it was expected that most clinicians would treat participants with AEs on the assumption that they had been
randomised to receive aspirin.
Interventions
Intervention group
Intervention: 300 mg of daily oral aspirin for 24 weeks (four × 75-mg tablets were encapsulated in size 00
capsules with added lactose and magnesium stearate blend as filler).
Control group
Placebo: daily oral placebo for 24 weeks. Size 00 capsules with lactose and magnesium stearate blend as
filler, which were identical in weight, colour and size to the aspirin capsules.
The full course of capsules (190 doses/capsules for 24 weeks’ treatment) were packaged into child-resistant
tamper-evident bottles. Participants were advised to take the capsules whole (not crushed or chewed),
once a day for 24 weeks or, if the reference ulcer was confirmed as healed before the end of 24 weeks,
a member of the medical team would advise them to stop taking the medication. The time of day for taking
the trial medication was not specified.
Participants were expected to receive and start their allocated trial treatment from 2 to 7 days after
randomisation.
All participants were offered an evidence-based standardised approach to the management of their leg
ulcers in accordance with Scottish Intercollegiate Guidelines Network (SIGN) guidance.33 This consisted of
multicomponent compression therapy aiming to deliver 40 mmHg of pressure at the ankle, when possible.
The type of dressing used was at the discretion of the health-care professionals managing the participants.
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Investigational medicinal product supply
The sponsor had responsibility for the order and purchase of trial medication and for arranging labelling of
medication for the trial with St George’s University Hospitals NHS Foundation Trust.
Manufacture, packaging and labelling
Active (aspirin) tablets were manufactured by Intrapharm Laboratories Limited, Maidenhead, UK.
Overencapsulation of the 75-mg tablets and production of the matching placebo capsules was performed
by Sharp Clinical Services (UK) Limited (MA IMP licence number 10284). Sharp Clinical Services (UK)
Limited performed all manufacturing and packaging operations in accordance with good manufacturing
practices derived from the rules governing Medicinal Products in the European Community and Good
Manufacturing Practice for Medicinal Products.34–36
The AVURT IMP was assigned an expiry date of 31 May 2016. Following the extension to participant
recruitment, the sponsor arranged for stability testing of the IMP with Sharp Clinical Services (UK) Limited.
The testing was conducted and the expiry date was extended to 31 January 2017.
The supplies of aspirin and placebo capsules were delivered to the Research Pharmacy, where they were
stored and dispatched to all participants.
Outcomes
Primary outcome
Time to healing of the reference ulcer (the largest eligible ulcer).
Secondary outcomes
l Ulcer size (area) measured in cm2 by specialist software and grid tracings.
l Following healing of the reference ulcer, recurrence of ulcer on the reference leg (defined as a new
ulcer on the reference leg).
l Adverse events.
l Ulcer-related pain using a visual analogue scale (VAS).
l Treatment compliance (capsule count and nurse assessment of compression concordance).
l Resource use: number of visits to clinic and/or home visits and types of dressings used.
Baseline assessment
Following confirmation of a participant’s eligibility, and before randomisation, a baseline assessment was
conducted by the study or research nurse using the baseline CRF (see Appendix 7).
Participant details
Data on ethnicity were collected at baseline. Participants’ date of birth, gender and smoking status were
collected at screening. Participants’ contact details (name, address, telephone numbers and e-mail address)
and general practitioner (GP) details (name of GP, name of surgery and address) were recorded at the
recruiting site only.
Ulcer history and assessment
The last ABPI measurement of the reference leg (leg with the largest eligible ulcer) and date it was taken
were recorded, or it was noted that the ABPI was unable to be taken. When ABPI was incompressible,
other assessments to exclude PAD were permitted, including peripheral pulse examination/toe pressure/
Duplex ultrasonography in combination with clinical judgement, but these forms of assessments were not
recorded on the CRF.
METHODS
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Other items recorded were number of ulcers on the reference leg, approximate duration of reference ulcer
(years, months and weeks), how long ago since patient developed their first leg ulcer (years, months and
weeks), and total number of ulcer episodes on reference leg (leg with largest eligible ulcer) including the
reference ulcer (largest eligible ulcer). All ulcers on both legs were drawn onto a leg diagram and the
reference ulcer indicated.
Digital photographs and tracings
To measure ulcer area, a photograph and tracing of the reference ulcer were taken at baseline. Photographs
were taken with a Nikon Coolpix L3 (Nikon Corporation, Tokyo, Japan), in accordance with trial procedure
(see Appendix 8). Anonymised digital photographs were sent to the YTU using a secure electronic method.
Sites unable to use this method were able to send anonymised photographs on a memory card via a courier
service to the YTU or a collection could be made by one of the trial co-ordinators.
Tracings were taken using a fine-nibbed marker pen on a wound measurement grid composed of 1-cm2
squares (P12v2, ConvaTec, Uxbridge, Middlesex, UK). The wound area was calculated by the treating or
research nurse by totalling the number of squares and/or partial squares on the grid contained within the
traced ulcer area.
Participant mobility, anthropometry and diabetic status
The level of a participant’s mobility (walking and ankle mobility), their height (feet/inches or centimetres)
and weight (stones/pounds or kilograms) were recorded. If both metric and imperial measurements were
given, a check was conducted by the YTU to determine if they were equivalent. Any differences were
queried with the site. Body mass index [BMI (kg/m2)] was calculated using the formula: weight (kg) divided
by height squared (m2). The presence of type of diabetes mellitus (type 1 or 2) was recorded.
Current treatments received
Participants’ medications at baseline were recorded by the study research nurse in a medication diary
(see Appendix 9). The medication diaries were then given to participants for recording changes to non-trial
medication. The participants were asked to bring their diary along to each clinic assessment for review by
the study research nurse and site medical practitioner to check that participants were safe to continue with
the IMP. Medication data were not collected for analysis.
Participants’ current treatment(s) for their VLU were recorded (type of compression bandaging), as was the
level of ankle pressure compression being aimed for (mmHg) and the primary dressing in contact with
the ulcer.
Ulcer-related pain
Participants were asked to rate the intensity of any leg ulcer-related pain over the previous 24 hours using
the 21-point Box Scale (BS-21).37 The BS-21 is a VAS that is divided into units of five and ranges from a
value of 0 (no pain) to 100 (worst pain imaginable).
Resource use
The treating or research nurse recorded resource use on the CRFs. They initially recorded the type of
dressing administered and level of compression aimed for and subsequently, during follow-up, only
recorded a change in the type of dressing administered and/or level of compression.
Outcome assessments
Participants were followed up weekly or fortnightly, depending on their usual pattern of attendance at
clinic, for a minimum of 25 weeks post randomisation. Participants were not asked to make any additional
visits for the purposes of the trial. The participant weekly data collection file, made up of CRFs and forms,
was completed during follow-ups by research nurses or treating nurses (see Appendix 10). In addition,
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recorded in the file were the weeks in which participants missed or did not have an appointment,
the randomisation date, the date that the first IMP dose was taken and the time of day that the IMP
was generally taken. A summary flow chart of participant follow-up is shown at Appendix 11.
Planned participant follow-up was for 25 weeks post randomisation, but participants who had a wound initially
judged as healed in week 24 or 25 were followed up for 2 further weeks (26 and 27 weeks post randomisation,
respectively) to confirm healing. Table 1 summarises the schedule of assessments. All anonymised completed
CRFs were faxed or sent via the University of York’s secure electronic system to the YTU.
Measurement and verification of primary outcome measure
Time to healing of the reference ulcer
The treating or research nurse identified and monitored the reference ulcer. Healing was defined as complete
epithelial cover in the absence of a scab (eschar) with no dressing required. Healing was determined by the
treating nurse or research nurse and a digital photograph was taken of the wound area. Healing was reported
by the treating site on Form D (see Appendix 10) which was submitted to the YTU. Time to healing was
measured in days from the date of randomisation to the date that the ulcer was first assessed as healed. After
the treating or research nurse initially judged the ulcer to be healed, participants were followed up for a further
2 weeks, in accordance with the Food and Drug Administration guidelines,38 to confirm healing.
Measurement of secondary outcomes
Ulcer size
The reference ulcer was measured using wound grid tracings at screening, baseline and at final follow-up
and at other follow-up visits when a photograph could not be taken. Treating nurses calculated the ulcer
size by totalling the number of squares and/or partial squares on the grid contained within the traced ulcer
area size and reported the measurement in the CRFs.
Anonymised digital photographs were taken at baseline and at all weekly or fortnightly follow-up visits.
All digital images were checked and the ulcer size calculated using SigmaScan® software (Sigma Scan Pro
version 5.0, SigmaScan, Systat Software Inc., San Jose, CA, USA) by one researcher, Rachael Forsythe
(Specialist Registrar in Vascular Surgery, St George’s Hospital, London, UK) who was blinded to treatment
allocation.
Ulcer recurrence
Weekly follow-up CRFs were not completed for participants after their reference ulcer had been confirmed
as healed. To collect ulcer recurrence data, participants were given a card with contact details for their
recruiting site (see Appendix 12) and were asked to phone the clinic if they developed a new ulcer on their
reference leg. In addition, at week 25 post randomisation, the research nurse phoned participants whose
reference ulcer had healed, to collect data on leg ulcer recurrence. The date of recurrence of a new venous
ulcer on the reference leg was recorded (see Appendix 10, Form E).
Ulcer pain
Participants were asked to rate the intensity of any leg ulcer-related pain over the previous 24 hours using
the BS-21. Ulcer-related pain was collected at baseline and at weeks 4, 5 and 6 after randomisation. It was
thought that aspirin might have a positive effect on pain. We required one pain score at follow-up but
took measurements at three follow-up time points to allow for participants not being seen every week.
METHODS
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TABLE 1 Schedule of assessments
Study procedures Screening Baseline
During treatment (weekly for 25 weeks post randomisation)
Post treatment
(only participants
whose reference
leg ulcer was
judged as healed in
weeks 24 and 25)
Post treatment (only
participants whose
reference leg ulcer
was judged as
healed in week 25)
Week 1 Weeks 2–3 Weeks 4–6 Weeks 7–24 Week 25 Week 26 Week 27
Informed consent ✓
Inclusion/exclusion criteria ✓ ✓
Demographics ✓
Dispensing of IMP ✓
Medical history ✓ ✓
Concomitant medication ✓ ✓ ✓ ✓ ✓ ✓ ✓a ✓ ✓
AEs/side effects/change to health status ✓ ✓ ✓ ✓ ✓ ✓ ✓
Ulcer photographb ✓ ✓ ✓ ✓ ✓ ✓a ✓ ✓
Tracing of ulcer ✓ ✓ ✓a
Resource use: change to type of usual
care/compression bandage
administered
✓ ✓ ✓ ✓ ✓a ✓ ✓
Compliance ✓ ✓ ✓ ✓ ✓a
Pain score ✓ ✓
Ulcer reccurrence (only patients whose
leg ulcer was confirmed as healed
before week 25)
✓
a Data was not collected from patients whose reference leg ulcer healed earlier in the trial.
b If a digital photograph of the ulcer could not be taken, then a tracing of the ulcer was made instead.
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Participant compliance with treatment
To monitor treatment concordance with the IMP and compression, the treating nurses recorded in the
weekly CRFs (see Appendix 10) how often a participant was taking the capsules and, when applicable,
reasons for not taking them every day. Treating nurses also recorded whether or not a participant had
fully, had partially, or had not complied with compression therapy, with reason(s) for non-compliance
captured when possible.
At the end of the study, the remaining IMP or, in cases when participants had taken all the trial medication,
the empty container, was returned to the Research Pharmacy, which undertook a pill count. This
information was then forwarded to the YTU for inclusion in the analysis.
Resource use
At follow-up visits (weekly or fortnightly depending on a participant’s usual pattern of care), changes to
the level of compression therapy were recorded (see Appendix 10, Form A) and changes to the type of
primary dressing or bandaging (see Appendix 10, Form B). The number of times participants had other
wound consultations in the previous week was also recorded.
Patient safety
Each participant was regularly reviewed by their treating nurse and/or physician working closely with the
AVURT research team and was continually assessed for any increased dyspepsia, other gastrointestinal
symptoms, skin rashes and any other possibly linked AEs that could be attributable to the IMP.
Known side effects
Common side effects of aspirin as listed on the summary of product characteristics, which was supplied
by the IMP manufacturer (Intrapharm Laboratories Limited), included increased bleeding tendencies
and dyspepsia.
Adverse events: definitions
The following definitions were applied in the study.
Adverse event
l Any untoward medical occurrence in a patient or clinical trial participant who is administered an IMP
and which does not necessarily have a causal relationship with this treatment, and which may include
an exacerbation of a pre-existing illness.
l Increase in frequency or severity of pre-existing episodic condition.
l A condition (regardless of whether or not it was present prior to the start of the trial) that is detected
after trial drug administration (this does not include pre-existing conditions recorded as such at
baseline, continuous persistent disease or a symptom present at baseline).
Adverse reaction
l Any untoward and unintended responses to an IMP related to any dose administered.
Serious adverse event or serious adverse reaction
l Any AE or reaction that, at any dose, results in death.
l Any AE or reaction that, at any dose, is life-threatening (places the subject, in the view of the
investigator, at immediate risk of death).
METHODS
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l Any AE or reaction that, at any dose, requires hospitalisation or prolongation of existing hospitalisation
[hospitalisation is defined as an inpatient admission, regardless of length of stay, even if it is a
precautionary measure for observation (including hospitalisation for an elective procedure and for a
pre-existing condition)].
l Any AE or reaction that, at any dose, results in persistent or significant disability or incapacity
(substantial disruption of one’s ability to conduct normal life functions).
l Any AE or reaction that, at any dose, results in a congenital anomaly or birth defect (in offspring of
subjects or their parents taking the IMP regardless of time of diagnosis).
l Any AE or reaction that is related to another important medical condition.
Important medical events that may not be immediately life-threatening or result in death or hospitalisation
but may jeopardise the subject or may require intervention to prevent one of the outcomes listed in
Serious adverse event or serious adverse reaction was also considered serious.
Suspected unexpected serious adverse reaction
A suspected unexpected serious adverse reaction (SUSAR) is an adverse reaction (AR) that is classed in
nature as both serious and unexpected.
An unexpected AR is when both the nature and the severity of the event are not consistent with the
reference safety information (RSI) available for the IMP in question.
Assessments
At each follow-up appointment, the treating nurses asked participants if they had experienced any
changes in their health and indicated their response in the CRFs. Participants whose reference leg ulcer
had healed, and, therefore, were no longer receiving follow-up appointments, were contacted at week 25
post randomisation by a research nurse who collected information on AEs that the participant had
experienced since the last data collection point (see Appendix 10, Form E).
Details of the AEs/ARs were recorded in clinic notes and on AE logs held at the recruiting sites. The
causality, severity and expectedness assessment was conducted by medically qualified doctors at the sites
who were blind to treatment allocation in accordance with the following descriptions.
Causality assessment
l Definitely: there is clear evidence to suggest a causal relationship, and other possible contributing
factors can be ruled out.
l Probably: there is evidence to suggest a causal relationship, and the influence of other factors
is unlikely.
l Possibly: there is some evidence to suggest a causal relationship (e.g. the event occurred within a
reasonable time after administration of the trial medication). However, the influence of other factors
may have contributed to the event (i.e. the patient’s clinical condition, other concomitant events).
l Unlikely: there is little evidence to suggest that there is a causal relationship (e.g. the event did not
occur within a reasonable time after administration of the trial medication). There is another reasonable
explanation for the event (e.g. the participant’s clinical condition, or other concomitant treatments).
l Unrelated: there is no evidence of any causal relationship.
l Not assessable: note – if this description was used, then the sponsor assumed that the event was
related to the IMP until follow-up information was received from the investigator to confirm a definitive
causality assessment.
Any SUSAR assessed as related to the IMP was required to be reported to the sponsor, irrespective of how
long after IMP administration the reaction had occurred.
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Expectedness assessment
Assessment was based solely on the available RSI for the IMP and was described using following categories.
l Expected: an AE that is classed in nature as serious and that is consistent with the information about
the IMP listed in the RSI or clearly defined in the study protocol.
l Unexpected: an AE that is classed in nature as serious and that is not consistent with the information
about the IMP listed in the RSI.
All assessments were reviewed by the chief investigator using specific guidance notes from the National
Institute for Health Research (NIHR) clinical trials tool kit.39
Reporting
Non-serious and serious AEs were reported by the sites to the trial manager at the YTU on the sponsor’s
AE log. SAEs were recorded on the sponsor’s SAE form and reported directly to the sponsor (St George’s
University Hospital) within 24 hours of the local investigators becoming aware. The sponsor followed up
SAEs to their resolution and was responsible for reporting the events to Research Ethics Committee (REC),
the Medicines and Healthcare products Regulatory Agency (MHRA) and the trial manager at the YTU.
All AEs, ARs, SAEs and serious ARs were reviewed by the sponsor and chief investigator and subsequently
the DMC (blinded to allocation), which made the final decision regarding the severity and causality and
relationship between the event and treatment.
Withdrawal
Participants were deemed to have exited the trial when they:
l withdrew consent
l were lost to follow-up
l died
l had completed follow-up (i.e. 25 weeks post randomisation or, for patients whose leg ulcer was first
assessed as healed in weeks 24 and 25, weeks 26 and 27, respectively).
If a participant chose to withdraw from the trial then reasonable effort was made to establish the reason
for this withdrawal. For participants leaving the trial before final follow-up, nurses completed a change to
study status form (see Appendix 10, Form F), giving the main reason for the participant’s exit. No further
follow-up data were collected. Participants withdrawing from the study were given the option for their
data not to be used.
Participants stopped treatment for any one of the following reasons, but continued with follow-up:
l Unacceptable treatment toxicity that, in the investigator’s opinion, is attributable to the IMP or a SAE.
l Intercurrent illness that prevents further protocol treatment.
l Any change in a participant’s condition that, in the investigator’s opinion, justified the discontinuation
of treatment.
l If a participant became pregnant or suspected that they were pregnant.
l Reference ulcer confirmed as healed.
l A participant chose to discontinue treatment.
Participants whose leg ulcer was initially assessed as healed were encouraged to take the IMP during the
2-week observation period. If healing was confirmed after 2 weeks, the participant stopped taking the trial
medication and follow-up was suspended until a final follow-up in week 25.
METHODS
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Sample size
The target sample size was 100 participants. This sample size is sufficient to test the feasibility of study
procedures, such as recruitment and retention, and is large enough to demonstrate whether or not there is
evidence for efficacy in line with two previous trials of aspirin for leg ulcers.25,26
The primary outcome was time to healing of the largest eligible leg ulcer (reference ulcer). Ulcer area and
duration of ulcer are known prognostic factors for healing. In a previous leg ulcer study, Venous leg Ulcer
Study IV (VenUS IV), after adjustment for log-area of ulcer and log-duration of ulcer, the standard error for
the time to healing estimate was 0.105, with data on 448 participants.3 Applying this to a smaller sample
of 100 participants implies that the standard error of such a sample would be increased to 0.22 [obtained
from 0.105 ×√(448/100)]. A 95% confidence interval (CI) for the log-hazard ratio (HR) would thus be the
estimate of the log (HR) ± 1.96 × 0.222 = log(HR) ± 0.435. The antilog of this is 1.54 and the 95% CI for
the HR would be the observed value divided or multiplied by this. Hence, if our HR were the same as that
suggested by the existing studies (i.e. about 1.5), then our CI would be 0.97 to 2.31, which just includes 1.00.
It would be unlikely that, if the HR is as these two previous smaller studies suggest, we would observe an
overall HR of < 1.00. Compliance and follow-up were measured as part of the study and so there is no
formal inflation of the recruitment target for drop out.
A secondary outcome was change in wound area. Using data from the Venous leg Ulcer Study I (VenUS I)
of compression bandaging,40 ulcer area was measured for 245 participants who were measured within
60 days of recruitment. Ulcer area has a highly skewed distribution, so we calculated a difference in log-area
at follow-up, after adjustment for log-ulcer area at baseline and time elapsed until follow-up. The residual
standard deviation (SD) was 1.09. Two groups of 50 participants would give us 80% power to detect a
difference of 0.62 on the natural-log scale, corresponding to a reduction of 46% in ulcer area at follow-up.
In the current study, we had multiple measurements of wound area and so predicted that we should be able
to detect smaller differences.
Statistical methods
The statistical methods for the analysis of the trial data were prespecified and detailed in a statistical
analysis plan (SAP) before the completion of data collection. The SAP was prepared by the trial statisticians
and reviewed by members of the Trial Management Group (TMG) and DMC. However, given that the
final number of participants randomised was much lower than the 100 planned (n = 27), many of the
pre-planned analyses were infeasible or inappropriate. In this section, we describe the analyses as
performed, highlighting any deviations from the SAP.
Pre-screening, screening and eligibility data
The flow of participants through the trial is presented in a Consolidated Standards of Reporting Trials
(CONSORT) diagram.41 The number of patients who were pre-screened, were approached and consented is
reported. Reasons for ineligibility at the pre-screening phase and reasons for not consenting are summarised.
Baseline data
Participant characteristics and clinical baseline measurements are summarised descriptively overall and by
trial arm. These measures include age, gender, BMI, diagnosis of diabetes mellitus, ethnicity, participant’s
level of mobility and ankle mobility, reference ulcer size and corresponding stratification (≤ 5 cm2 or
> 5 cm2), time since first ulcer, duration of reference ulcer (actually referring to the duration of the ulcer
up to but not beyond randomisation), left/right reference leg, total ulcers on reference leg, ABPI of the
reference ulcer, levels of pain from the reference ulcer, current compression and dressing treatments.
Continuous measures were summarised using mean, SD, median, minimum, maximum and interquartile
range (IQR). Categorical measures were reported as counts and percentages. No formal statistical
comparisons of baseline factors by trial arm were undertaken.
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Primary outcome
The primary analysis investigated the difference in time to healing by trial arm using Cox’s proportional
hazards regression adjusted for ulcer area (cm2) and ulcer duration (days) at baseline, both logarithmically
transformed. Ulcer area and ulcer duration tend to have a skewed distribution and, therefore, a logarithmic
transformation is used to obtain a distribution that is closer to the normal. It was initially planned to
subsequently test for the inclusion of shared centre frailty effects; however, the final distribution of
participants across centres (see Table 2) made the frailty model an impractical choice for this analysis.
Therefore, only the Kaplan–Meier survival curve, the log-rank test and the Cox’s regression model, both
unadjusted and adjusted for the logarithm of the area and of the ulcer duration, were undertaken. HRs,
corresponding 95% CIs and p-values for the model covariates are presented.
Secondary outcomes
Adverse events
Adverse events were reported overall and by trial arm in terms of number of participants with at least one
event and total number of events. Serious and non-serious events were presented separately and according
to whether or not they were thought to be related or unrelated to treatment. For SAEs, reasons for the
serious nature of the events were reported. Differences in total number of events by trial arm were
compared using negative binomial regression adjusted for size and duration of ulcer (both log transformed).
Ulcer size
The area resulting from the analysis with the SigmaScan was used in statistical analysis whenever available.
In the case when a photograph could not be taken, the measure of the ulcer area was obtained by using
the tracing of the ulcer, if available. The area at baseline and at each assessment is summarised using
descriptive statistics (mean and SD) for each trial arm and overall. A plot containing means and 95% CIs
for both trial arms was also produced with lower confidence limits truncated at zero, as wound area can
only be positive.
It was planned a priori that the logarithm of the ulcer area would be investigated via a repeated measures
mixed model to see if there were any differences by trial arm; however, owing to the low number of
participants and the high number of time points, this model was not judged to be appropriate for the
final analysis.
Ulcer recurrence
As a recurrence of the reference ulcer was reported for only two participants, the Cox proportional hazards
regression initially planned was not performed. For both participants the number of days from healing to
recurrence is presented.
Time to first investigational medicinal product dose
The median time in days from randomisation to date the first IMP dose was taken was presented alongside
95% CI by trial arm and overall.
Time of day
The number of participants who reported taking their study drug in the morning, afternoon and evening is
summarised using counts and percentages.
Ulcer pain
The VAS scale [from 0 (no pain) to 100 (worst pain imaginable)] to measure pain was used at baseline and
at weeks 4, 5 and 6 in order to increase the likelihood of capture, as not all patients were seen weekly. Only
one VAS score was used for the analysis: if the week 5 VAS score was present, this was used; if it was not
and either only week 4 or only week 6 were provided, then the corresponding VAS score was used; if both
week 4 and week 6 were provided but week 5 was not, then the VAS completed on the closest date to
week 5 was taken; if both weeks were completed an equidistance from week 5, then week 4 was taken.
METHODS
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Descriptive statistics of VAS score (mean, SD, median, minimum, maximum, IQR) were calculated overall
and for each trial arm at baseline and at week 5, obtained as defined above. A plot of the means and
95% CIs for both trial arms at baseline and at week 5 was produced.
The planned linear regression analysis, aimed to compare differences in pain scores between allocated
groups, was not performed owing to low numbers.
Participant compliance with treatment
At each assessment visit, compliance with both the compression therapy (for those receiving this
treatment) and with the study capsules was recorded. This was via the following two questions: ‘Has the
participant complied with their [compression therapy] treatment’ (fully/partially/not at all), and ‘How often
has the participant taken their AVURT capsules (300-mg aspirin/placebo per day) this week?’ (every day/
most days/some days/not at all). The responses to both of these questions were given numerical values:
fully = 1, partially = 2, and not at all = 3; and every day = 1, most days = 2, some days = 3, and not at
all = 4. To calculate compliance with compression treatment, the responses across all weeks up to healing/
trial exit were summed and divided by the number of visits attended to obtain the mean compliance level
for each participant. This compliance level was then categorised as fully compliant if the mean value was 1,
partially compliant if the value was between 1 and 3 (not inclusive), and not at all compliant if the value
was equal to 3. The number and percentage of participants in each of these categories is presented.
Compliance with study capsules was analysed similarly but only considering responses in the weeks
following delivery of the capsules. The compliance level was categorised as fully compliant if the mean
value was 1, partially compliant if the value was between 1 and 4 (not inclusive), and not at all compliant
if the value was equal to 4. Reasons for lack of full compliance are presented.
The second way that compliance with AVURT capsules was assessed was through the use of the count
of the returned capsules at the end of the study. Each participant was given 190 capsules and by subtracting
the number of returned pills it was possible to obtain an estimate of the number of capsules actually taken.
The number of capsules that should have been taken was calculated starting from the date of first dose until
2 weeks after healing (for those who had healed) or the date of the last visit (for those who did not heal).
From this, the percentage of capsules that each participant took (of those they should have taken) was
calculated. The level of compliance was split into 11 categories (100%, 90–99%, 80–89%, etc.) and the
count and percentage of patients falling in each category is presented (see Tables 13 and 14).
Resource use
Level of compression therapy
The number of changes to compression therapy is presented overall and by trial arm, and also stratified by
time to healing (or censoring) using the categories 0–2 months, > 2 to 4 months, and > 4 months. The
number and percentage of changes to low/medium/high or no compression therapy are presented overall
and by trial arm.
Bandaging and hosiery
The number and percentage of changes to each bandage type are presented overall and by trial arm,
as are the number and percentage of patients who received each type of bandaging at least once during
the study.
Dressing
The number of changes per participant to dressing type is summarised overall and by trial arm, and stratified
by time until healing (or censoring) using the categories 0–2 months, > 2 to 4 months, and > 4 months.
The number and percentage of changes to each dressing type are presented overall and by trial arm, as are
the number and percentage of patients who received each type of dressing at least once during the study.
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Wound consultations
For each participant, the number of wound consultations per week was calculated by summing the number
of consultations the participant had in the previous week, declared on the weekly CRFs, plus the visit in which
the CRF was completed and dividing it by the number of visits actually attended. The mean number of wound
consultations per week is presented alongside SD, median, minimum, maximum and IQR (see Table 22).
Approvals obtained and governance
Ethics and Medicines and Healthcare products Regulatory Agency approvals
The trial was approved by Nottingham REC on 29 January 2015 (REC reference number 14/EM/1305)
and by the University of York Health Science Research Governance Committee on 16 February 2015. The
MHRA approved the study on 26 March 2015 (MHRA reference 16745/0221/001-001). The London Local
Research Network completed their global checks on 7 May 2015 and thereafter research governance
approval was obtained from each trial centre. The trial was registered with ClinicalTrials.gov and assigned
the number NCT02333123, and with the European Clinical Trials Database and assigned the European
Clinical Trials Database (EudraCT) number 2014-003979-39.
Trial monitoring
The AVURT was monitored by the sponsor, St George’s University of London. The trial was conducted
and monitored in compliance with their standard operation procedures:42 International Conference on
Harmonisation Harmonised Tripartite Guidelines For Good Clinical Practice E6 (ICH GCP) and the Medicines
for Human Use (Clinical Trials) Regulations 2004 (SI 2004/03) (as amended).
The purpose of the monitoring was to ensure:
l the safety and welfare of trial participants
l that trial data were accurate and verified from source data when possible
l that the trial was compliant with good clinical practice and other regulatory requirements.
Trial oversight
The trial was overseen by the TMG, the Trial Steering Committee (TSC) and the DMC.
Trial Management Group
The TMG was responsible for project oversight, directing the management of the trial and reviewing
progress. The TMG was chaired by the chief investigator and comprised the trial co-ordinators, trial
statisticians and the majority of the coapplicants including a patient representative.
Trial Steering Committee
The TSC provided overall supervision of the progress of the trial towards its interim and overall objectives,
to ensure adherence to the protocol and patient safety. The TSC approved the trial protocol prior to
participant recruitment, reviewed recruitment, protocol deviations, the trial’s results and recommendations
made by the DMC.
The TSC was chaired by an independent representative (Professor Julie Brittenden) and membership
consisted of three other independent members, a patient representative and members of the research team,
including the chief investigator, the sponsor’s representative, the trial statistician and trial co-ordinators. The
TSC met for the first time prior to participant recruitment and then three times during the course of the trial.
Data Monitoring Committee
The main role of the DMC was to ensure the safety of trial participants, to protect the validity of the trial,
to advise the investigators and to make recommendations to the TSC about whether or not the trial should
continue. The DMC approved the SAP and reviewed recruitment figures, protocol deviations, protocol
amendments and AE data.
METHODS
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The DMC was chaired by an independent representative (Professor Peter Franks) and membership
consisted of three other independent members and members of the research team, including the chief
investigator, the sponsor’s representative, the trial statistician and trial co-ordinators.
Patient and public involvement
At the grant application stage, the views of six patients attending a leg ulcer clinic were elicited.
Specifically, they were asked for their views on the likely willingness of patients to take aspirin on a daily
basis, given its possible side effects, if it were shown to improve healing of leg ulcers. All responded that
they would be willing to take medication if it meant that their ulcer was likely to heal more rapidly. They
thought that the risks of aspirin were acceptable given that many patients already take it regularly for
cardiovascular disease. In terms of a trial, they thought that they would be happy to receive a dummy
tablet (placebo) if it meant that more information could be gleaned about the efficacy of aspirin in terms
of healing ulcers – even though a further larger trial might be required to confirm the results. Some
patients questioned the benefit about taking a high dose of aspirin. However, the feeling expressed by
some was that the perceived increased risks would be worthwhile if it significantly decreased time
to healing.
There were two patient coapplicants. Ellie Lindsay, president of the Leg Club Foundation, was a member
of the TMG, and our other patient representative, Laurie Williams, was a member of the TSC. Both were
involved in the development of the trial during the application stage and throughout the study. They were
also involved in the development of the trial’s patient information resources.
Protocol amendments
Amendments to the protocol were required by REC prior to approval. Following approval, no substantial
amendments were made to the protocol. Details of all ethics and MHRA amendments are detailed in
Appendix 13.
DOI: 10.3310/hta22550 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 55
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Tilbrook et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19

Chapter 3 Results: feasibility of recruitment
The original participant recruitment window was for 6 months and was due to finish on 30 September2015. Owing to delays in sites opening and to allow the last few sites to open sufficient time to recruit,
this was extended to an 8-month recruitment window. Consequently, to allow the full follow-up of all
participants, the total duration of the trial was extended by just over 5 months to 14 December 2016
(the project was originally due to close on 30 June 2016).
Site recruitment
Ten sites opened to recruitment. Prior to recruitment, the sites indicated the approximate number of
participants they could recruit (see Appendix 1). Recruitment was largely based in leg ulcer community
clinics and hospital outpatient clinics. Many of the recruiting sites were chosen as they had been high
recruiters to other leg ulcer studies.
Eleven sites were initially interested in participating. Nottingham University Hospitals NHS Trust
subsequently declined after undertaking a complete screening review of its patient population, which
consisted of 3300 patients referred with chronic oedema of all forms with many suffering from venous leg
ulceration. An analysis of their patient profile indicated that they would have little access to non-complex
patients. The remaining 10 sites were submitted to REC for approval:
1. St George’s Healthcare NHS Trust London
2. Bradford Teaching Hospitals NHS Foundation Trust
3. Leeds Community Healthcare NHS Trust
4. Newcastle upon Tyne Hospitals NHS Foundation Trust
5. Cardiff & Vale University with Aneurin Bevan University Health Board (Newport)
6. Hull and East Yorkshire Hospitals NHS Trust
7. Harrogate and District NHS Foundation Trust
8. Mid Yorkshire Hospitals NHS Trust (Wakefield)
9. Lancashire Care NHS Foundation Trust
10. Sussex Community NHS Trust (Brighton).
Sites were opened throughout the participant recruitment phase and, of these sites, three (Bradford, Leeds
and Wakefield) did not open but were in various stages of contracts, training, site initiation visits and
approvals when the trial closed to recruitment. During the recruitment phase, we received interest from
three other sites that opened after they received REC and local research and development (R&D) approvals:
NHS Tayside (Dundee), NHS Lanarkshire and Kent Community Health NHS Foundation Trust. We were also
in discussion with Birmingham Community Healthcare NHS Trust towards the end of the recruitment phase.
Barriers to recruitment
The first site opened to recruitment on 23 June 2015, almost 3 months later than scheduled. Barriers to
recruitment included a delayed start due to issues releasing the IMP. Because there was uncertainty about
when the IMP would be available, we were unable to confirm a start date for recruitment. Sites were
expected to recruit their first patient within 35 days of submission of their site specific information forms
to their local R&D. Local checks were likely to include the availability of the IMP. Once the IMP had been
released, there was a slow rate of sites opening over the summer owing to staff availability at the sites.
At three sites key staff were on long-term leave or had left and were waiting for new staff to be appointed
before proceeding.
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Participant recruitment
Once open to recruitment there were fewer than expected eligible patients at sites. The pre-screening data
from sites indicated various and multiple reasons for patients not being approached (Figure 1). The main
reasons for participant ineligibility were:
l already taking aspirin or other prohibited medication
l having a small or otherwise ineligible ulcer.
In the last few months of recruitment, when all sites were open, the trial was recruiting three to five
participants per month (see Appendix 14). It was generally thought by some sites that a large proportion
of leg ulcer patients were receiving treatment in general practices (i.e. in primary care) or outside primary
care in specialist clinics and by district nurses. It was therefore likely that the patients being seen by the
secondary recruiting sites were older, more likely to have mixed disease and, therefore, more likely
to be already taking aspirin.
Strategies to improve recruitment
Strategies to improve recruitment were explored. Modification of the eligibility criteria was assessed with
reference to the pre-screening log data. The only acceptable modification to the exclusion and inclusion
criteria was to include a smaller wound size. However, those with a wound area of < 1 cm2 were excluded,
as these ulcers usually heal very rapidly.
In October and November 2015, the chief investigator and a trial manager contacted the recruiting
sites that had been the first to open (Kent, Hull, Brighton, Harrogate and Newcastle) to discuss possible
solutions to improve participant recruitment. During meetings with sites, a number of ideas were
discussed, including:
l Advertising via social media.
l Posters to inform patients about the study.
l Newsletter for sites.
l Flyers for sites to remind staff to recruit to the study.
l Radio advertising (Hull and Harrogate).
l An amendment to protocol to allow participants to visit sites for follow-up purposes (the protocol
stated that patients will not be invited to attend clinics for research purposes), and to introduce
per-patient payments for visits that were not part of routine care. This was a particular problem for
one site (Newcastle) that did not routinely see patients in clinic after their initial visit.
l Allowing for more telephone follow-ups so that participants did not need to come in to clinic as
regularly as once per week or once per fortnight.
l Remove minimum ulcer size from the eligibility criteria, in line with the study being conducted in
New Zealand.29
Apart from removing the minimum ulcer size criterion, each of the options considered would have
potentially benefited just one or two of the recruiting sites and, therefore, a variety of strategies would
need to be implemented across the trial. The funder and REC had required for regular follow-up to
monitor patient safety and, therefore, less frequent follow-up was not viewed as a feasible option by the
research team.
A flyer was produced and sent to sites to remind clinic staff to recruit to the trial (December 2015) and
three electronic newsletters were sent to sites (two during recruitment, in October 2015 and December 2015)
to update on participant recruitment in the trial (the third newsletter was sent in June 2016 after recruitment
had closed). The flyer and newsletters were relatively cheap to produce and did not require ethics approval
RESULTS: FEASIBILITY OF RECRUITMENT
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and so could be sent out swiftly. During training, sites were reminded to identify potential participants
before opening so that the participants could be approached as soon as the sites were given the green light
to recruit.
Recruitment from primary care
We explored recruitment from primary care, which was supported by the trial’s DMC. Two options were
considered: to use general practices to identify patients and refer them to the secondary care sites already
participating in the study (PICs) or to use general practices as recruitment and treatment centres.
The chief investigator approached the NIHR National Speciality Lead for Primary Care in December 2015 to
explore how they might be able to support the study and to request some initial pre-screening to see how
many patients could be identified in primary care. The NIHR Clinical Research Network, South London, UK,
contacted a number of general practices on our behalf with the trial protocol including the inclusion and
exclusion criteria and received three responses:
l One Clinical Commissioning Group provided comments on the difficulty of identifying potential
patients using a database search as many of the eligibility criteria, for example size of ulcer and
duration of ulcer, are not coded. We were also advised that many patients were taking aspirin over the
counter and that this may not currently be recorded in some patients’ records.
l Two general practices identified a total of three potential participants in total.
We also approached Clinical Research Network Yorkshire and Humber who ran the trial’s inclusion and
exclusion criteria through FARSITE (version 0.9.12.2; NorthWest EHealth Limited, Manchester, UK;
https://nweh.co.uk/how-we-do-it/our-technology), a web-based anonymous search of patient records.
They identified four suitable patients from 12 general practices.
We were unable to obtain details of practice list sizes, Read codes or criteria used in the searches
conducted. However, the results indicated that recruitment from primary care was not a viable option
using database searches. In addition, two of the recruiting sites (Lanarkshire and Sussex) advised that they
would be unable to support referrals from primary care, which at one site was owing to waiting lists
already for the service.
Recruitment using general practices as treatment centres was not investigated. Time constraints and
budget constraints for implementing this strategy meant that this was option was not explored.
Summary
There were external factors outside the control of the research team that meant that sites were slow to
open. Nine out of the 10 recruiting sites were based in secondary care and, once open, there were fewer
than anticipated eligible participants. As this was a Clinical Trial of an Investigational Medicinal Product
(CTIMP) study, it required more input from a doctor where nurses would otherwise often take the lead.
The site make up was very different from other wound trials in which almost all sites were community
based with tissue viability nurses acting as principal investigator, which was not possible here. A range of
options were considered and explored to improve recruitment, including recruitment from primary care.
Preliminary searches of records in primary care also indicated very few potentially eligible participants.
In addition, the trial’s short recruitment window and budget constraints meant that many of the options
considered to improve recruitment were not viable without a funded extension.
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Chapter 4 Results
Analyses were conducted following the principles of intention to treat with all events analysed accordingto the participant’s original treatment allocation. Analyses were performed using Stata® version 14
(StataCorp LP, College Station, TX, USA). The trial opened to recruitment on 23 June 2015 and closed to
recruitment on 29 February 2016. Participant follow-up was completed on 18 August 2016.
Participant flow
The CONSORT diagrams in Figures 1 and 2 show the flow of participants pre-screened and the flow of
eligible participants during the trial. Figure 1 illustrates the number of patients pre-screened (n = 457) and
the number of those who consented (n = 20). Pre-screening data were unavailable for the nine remaining
patients who consented. Pre-screening was under-reported because some sites did not complete the first
pre-screening log. The flow of participants in the trial is illustrated in Figure 2, which shows that 29 patients
consented. The number of patients randomised by treatment group, receiving the intended treatment,
completing the study protocol, and analysed for the primary outcome is presented. Two patients were
excluded after they gave consent: one patient developed potential gastric problems and the other patient,
affected by multiple comorbidities, was admitted to hospital.
Not approachedb
(n = 392)
• Taking aspirin, n = 110
• Wound of ≤ 1 cm2, n = 78
• Wound duration of < 6 weeks and no history 
   of venous ulceration, n = 24
• Non-venous/mixed aetiology, n = 28
• Prohibited medication, n = 76
• Intolerance/contraindication to aspirin, n = 11
• Foot ulcer, n = 9
• Not expected to be compliant, n = 26
• ABPI of < 0.8, n = 4
• No ulcer present or already healed, n = 28
• Other, n = 61
Did not consent/ineligible
(n = 45)
• Ineligible, n = 10
• Declined, n = 16
• Other disease, n = 3
• Not contactable, n = 4
• Other reason, n = 7
• No reason given, n = 5
Number of patients pre-screened
(n = 457)a
Approached
Consent
Pre-screening
Consent taken
(n = 20)
Approached
(n = 65)
FIGURE 1 The AVURT pre-screening study flow. a, The actual number of patients pre-screened was higher than
457 as the first version of the pre-screening log was not mandatory; and b, reasons not mutually exclusive.
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Recruitment
Recruitment took place over 8 months, 2 months longer than originally scheduled. The trial opened on
23 June 2015 and the first participant was recruited on 13 July 2015. Recruitment closed on 29 February 2016.
In total, 10 sites were opened and eight randomised a total of 27 patients (Table 2). The sites in Cardiff and
Dundee did not recruit any participants. For accumulative recruitment over time see Appendix 14.
Baseline data
The baseline participant and ulcer-related characteristics, as well as the baseline treatments, are shown in
Tables 3–5. The average age of the 27 randomised participants was 62 years (SD 13 years) and two-thirds
were male (n = 18). Participants had had their reference ulcer for a median of 15 months and the median
size of ulcer was 17.1 cm2. All participants were receiving compression therapy at baseline.
Withdrawals and losses to follow-up
Withdrawals and losses to follow-up were recorded on a change of status form (see Appendix 10, Form F)
for five patients (placebo, n = 3; aspirin, n = 2). However, there was only one withdrawal during the course
of the study (who was in the placebo group) for whom data on primary outcome was not possible to obtain.
This was reported at week 2 and so no follow-up data are available for this participant beyond week 1.
The other four participants (placebo, n = 2; aspirin, n = 2) either agreed to withdraw from treatment but
provided full follow-up until week 25 (i.e. the end of planned follow-up) or healed at a point before
withdrawal and, thus, all four provided primary outcome data.
Overall, this means that, in terms of analyses related to primary outcome, only one patient was not
included (see Figure 2).
Consent taken
(n = 29)
Analysed
(n = 12)
Further withdrawals
(n = 0)
Allocated to placebo
(n = 13)
• Received placebo, n = 12
• Did not receive placebo, n = 1 
   (full withdrawal at week 1; 
   trial drug not received)
Further withdrawals
(n = 0)
Allocated to aspirin
(n = 14)
• Received aspirin, n = 14
• Did not receive aspirin, n = 0
Analysed
(n = 14)
Allocation
Analysis
Follow-up
Randomised
(n = 27)
Consent
Screening
Randomisation
Assessed for eligibility
(n = 29) Excluded for health-
related problems after
consent was given
(n = 2)
FIGURE 2 The AVURT CONSORT diagram.
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TABLE 2 Randomised participants by centre
Centre Participants, n (%)
London, St George’s 7 (25.9)
Hull and East Yorkshire 6 (22.2)
Newcastle 3 (11.1)
Lancashire 3 (11.1)
Kent 3 (11.1)
Harrogate 2 (7.4)
Brighton 2 (7.4)
Lanarkshire 1 (3.7)
Cardiff 0 (0)
Dundee/Tayside 0 (0)
Total 27 (100.0)
TABLE 3 Baseline data: participant characteristics
Participant characteristic
Group
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Age (years)
Mean (SD) 62.1 (15.2) 62.7 (11.6) 62.4 (13.2)
Median (minimum, maximum) 66.6 (38.9, 80.8) 59.2 (47.9, 78.9) 62.0 (38.9, 80.8)
IQR (25%, 75%) (50.2, 73.4) (54.0, 74.4) (50.4, 74.4)
Missing, n (%) 0 (0) 0 (0) 0 (0)
Gender, n (%)
Male 7 (53.9) 11 (78.6) 18 (66.7)
Female 6 (46.2) 3 (21.4) 9 (33.3)
Missing 0 (0) 0 (0) 0 (0)
BMI (kg/m2)
Mean (SD) 32.1 (8.6) 36.6 (15.0) 34.4 (12.3)
Median (minimum, maximum) 28.4 (19.9, 44.1) 31.6 (20.9, 70.2) 31.5 (19.9, 70.2)
IQR (25%, 75%) (25.3, 40.6) (25.9, 40.2) (25.3, 40.6)
Missing, n (%) 0 (0) 0 (0) 0 (0)
continued
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TABLE 3 Baseline data: participant characteristics (continued )
Participant characteristic
Group
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Mobility, n (%)
Patient walks freely 10 (76.9) 8 (57.1) 18 (66.7)
Patient walks with difficulty 3 (23.1) 6 (42.9) 9 (33.3)
Patient is immobile 0 (0) 0 (0) 0 (0)
Missing 0 (0) 0 (0) 0 (0)
Ankle mobility of reference leg, n (%)
Patient has full range of motion 7 (53.9) 11 (78.6) 18 (66.7)
Reduced range of ankle motion 6 (46.2) 3 (21.4) 9 (33.3)
Patient’s ankle is fixed 0 (0) 0 (0) 0 (0)
Missing 0 (0) 0 (0) 0 (0)
Diabetic, n (%)
Yesa 2 (15.4) 3 (21.4) 5 (18.5)
No 11 (84.6) 11 (78.6) 22 (81.5)
Missing 0 (0) 0 (0) 0 (0)
Ethnicity, n (%)b
White British 11 (84.6) 12 (85.7) 23 (85.2)
White Irish 1 (7.7) 0 (0) 1 (3.7)
Indian 0 (0) 1 (7.1) 1 (3.7)
Black African 1 (7.7) 1 (7.1) 2 (7.4)
Missing 0 (0) 0 (0) 0 (0)
a All participants with diabetes mellitus had type 2 diabetes mellitus.
b Other categories included on CRF but not ticked: white – other European, any other white background, white and black
Caribbean, white and black African, white and Asian, any other mixed background, Pakistani, Bangladeshi, any other
Asian background, black Caribbean, any other black background, Chinese, Japanese, and other.
TABLE 4 Baseline data: ulcer related
Ulcer-related characteristic
Group
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Size of ulcer (cm2)
≤ 5 cm2, n (%) 3 (23.1) 3 (21.4) 6 (22.2)
> 5 cm2, n (%) 10 (76.9) 11 (78.6) 21 (77.8)
Mean (SD) 40.7 (55.1) 43.1 (47.6) 42.0 (50.3)
Median (minimum, maximum) 16.0 (2.0, 173.0) 31.3 (3.8, 155.0) 17.1 (2.0, 173.0)
IQR (25%, 75%) (6.5, 45.0) (7.0, 45.0) (6.5, 45.0)
Missing,a n (%) 0 (0) 0 (0) 0 (0)
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TABLE 4 Baseline data: ulcer related (continued )
Ulcer-related characteristic
Group
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Time since first ulcer (months)
Mean (SD) 112.5 (78.5) 86.4 (86.9) 99.0 (82.4)
Median (minimum, maximum) 101.0 (11.0, 240.0) 48 (2.2, 240.0) 72.0 (2.2, 240.0)
IQR (25%, 75%) (60.0, 168.0) (18.0, 192.0) (19.0, 192.0)
Missing, n (%) 0 (0) 0 (0) 0 (0)
Reference ulcer duration (months)
Mean (SD) 58.6 (73.3) 32.2 (52.0) 44.9 (63.3)
Median (minimum, maximum) 13.0 (4.0, 234.0) 16.5 (1.8, 192.0) 15.0 (1.8, 234.0)
IQR (25%, 75%) (8.0, 72.0) (3.5, 24.0) (6.0, 60.0)
Missing, n (%) 0 (0) 0 (0) 0 (0)
Reference leg, n (%)
Left 5 (38.5) 8 (57.1) 13 (48.2)
Right 8 (61.5) 6 (42.9) 14 (51.9)
Missing 0 (0) 0 (0) 0 (0)
Ulcers on reference leg
Mean (SD) 2.4 (1.7) 2.4 (1.7) 2.4 (1.7)
Median (minimum, maximum) 2.0 (1.0, 7.0) 2.0 (1.0, 6.0) 2.0 (1.0, 7.0)
IQR (25%, 75%) (1.0, 3.0) (1.0, 3.0) (1.0, 3.0)
Missing, n (%) 0 (0) 0 (0) 0 (0)
Ulcer episodes on reference leg
Mean (SD) 1.8 (1.1) 2.3 (1.9) 2.1 (1.5)
Median (minimum, maximum) 1.0 (1.0, 4.0) 1.0 (1.0, 6.0) 1.0 (1.0, 6.0)
IQR (25%, 75%) (1.0, 2.0) (1.0, 4.0) (1.0, 3.0)
Missing, n (%) 0 (0) 0 (0) 0 (0)
ABPI
Mean (SD) 1.1 (0.2) 1.0 (0.1) 1.0 (0.2)
Median (minimum, maximum) 1.0 (0.8, 1.5) 1.0 (0.9, 1.3) 1.0 (0.8, 1.5)
IQR (25%, 75%) (0.9, 1.2) (0.9, 1.1) (0.9, 1.2)
Missing, n (%) 2 (15.4) 2 (14.3) 4 (14.8)
Ulcer-related pain (0–100 VAS)b
Mean (SD) 37.7 (25.9) 45.4 (36.0) 41.7 (31.2)
Median (minimum, maximum) 30.0 (5.0, 80.0) 47.5 (0.0, 100.0) 35.0 (0.0, 100.0)
IQR (25%, 75%) (15.0, 60.0) (10.0, 70.0) (10.0, 70.0)
Missing, n (%) 0 (0) 0 (0) 0 (0)
a Missing for one patient on baseline CRF, value estimated as agreed a priori from average of reviewed photographs.
b Pain intensity over the last 24 hours (VAS scale: 1–100, in steps of 5).
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Primary outcomes
Overall, 13 out of the 26 (50.0%) participants followed up were recorded as healing during the course
of the study. All the reference ulcers reported to be healed were later confirmed healed approximately
2 weeks later. The first date of reported healing (as reported on the weekly CRF data collection) was used
in the statistical analysis (as per the SAP).
Over the course of the trial, 7 out of 12 participants (58.3%) followed in the placebo group were
observed to have a healed reference ulcer, and in the aspirin group the corresponding figure was 6 out
of 14 (42.9%). It was not possible to estimate median time to healing and/or corresponding 95% CIs as
TABLE 5 Baseline data: compression treatment
Compression treatment characteristic
Group, n (%)
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Level of ankle pressure compression
Low (≤ 19mmHg) 0 (0) 0 (0) 0 (0)
Medium (20–39mmHg) 0 (0) 2 (14.3) 2 (7.4)
High (≥ 40mmHg) 13 (100) 12 (85.7) 25 (92.6)
Missing 0 (0) 0 (0) 0 (0)
Compression bandaging
Four layer 6 (46.2) 7 (50.0) 13 (48.2)
Three layer 1 (7.7) 0 (0) 1 (3.7)
Three-layer reduced compression 0 (0) 1 (7.1) 1 (3.7)
Reduced compression 0 (0) 1 (7.1) 1 (3.7)
Two-layer hosiery 2 (15.4) 0 (0) 2 (7.4)
Reduced compression therapy 0 (0) 0 (0) 0 (0)
Othera 4 (30.8) 5 (35.7) 9 (33.3)
Missing 0 (0) 0 (0) 0 (0)
Primary dressing
Silver containing 4 (30.8) 3 (21.4) 7 (26.0)
Iodine containing 2 (15.4) 3 (21.4) 5 (18.5)
Honey containing 0 (0) 1 (7.2) 1 (3.7)
Alginate 1 (7.7) 0 (0) 1 (3.7)
Soft polymer 1 (7.7) 0 (0) 1 (3.7)
Hydrocolloid 0 (0) 2 (14.3) 2 (7.4)
Basic wound contact 3 (23.0) 3 (21.4) 6 (22.2)
Other antimicrobial dressingb 1 (7.7) 0 (0) 1 (3.7)
No dressingc 1 (7.7) 2 (14.3) 3 (11.1)
Missing 0 (0) 0 (0) 0 (0)
a Actico; full compression (two-layer bandaging k-soft and actico); actico compression 10-cm double spiral as ankle
circumference > 25 cm; K two reduced; full compression 30 cm + ankle; short stretch actico; K-Z two-layer compression;
single actico – delivers 40 mmHg; Coban 2 layer (full compression).
b Cutimed sorbact.
c Impregnated in coflex bandage.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
< 50% of participants healed during the 25- to 27-week maximum follow-up period of the study (Table 6).
Therefore, the 25th percentile of time to healing was also estimated. Figure 3 shows the unadjusted
Kaplan–Meier plot of proportion of reference ulcers healed over time. The unadjusted log-rank test
investigating the difference between the survival curves showed no statistically significant difference (test
statistic = 1.02; p = 0.30).
The primary analysis as written in the SAP investigates difference in time to healing using a Cox model
adjusting for baseline ulcer area, baseline ulcer duration and centre. The covariates in this model were to
be baseline area and duration of the reference ulcer (planned log transformation), randomised allocation
and centre as a shared frailty effect. The model was originally chosen with a view to recruiting the target of
100 participants (if successful to follow with a larger definitive study) and was based on analyses performed
for the VenUS IV study, which enrolled 457 participants. Given the final distribution of participants across
centres (26 participants across eight centres, with six centres contributing three or fewer participants), the
shared frailty model is an impractical choice for this analysis. Adjustment with centre as a covariate alongside
ulcer area and duration would yield a very low number of events per variable (at approximately four events)
and lower than the 10 events that has been previously recommended from simulation studies using Cox
regression.43 Therefore, we present the Kaplan–Meier curves (see Figure 3), log-rank test and unadjusted
Cox regression as planned but caution against over-interpretation; we also present the results from the Cox
regression adjusted for log-area and log-ulcer duration but without adjustment for centre, giving HRs and
corresponding 95% CIs (Table 7).
TABLE 6 Healing of the reference ulcer (unadjusted analysis)
Outcome Placebo (N= 12)a Aspirin (N= 14) Overall (N= 26)
Number healing, n (%) 7/12 (58.3) 6/14 (42.9) 13/26 (50.0)
Kaplan–Meier estimate of median time to healing
(days) (95% CI)
98 (21 to NE) NE (84 to NE) 147 (97 to NE)
Kaplan–Meier estimate of 25th percentile time to
healing (days) (95% CI)
36 (20 to 97) 111 (69 to NE) 84 (21 to 111)
NE, not possible to estimate.
a One participant was lost to follow-up immediately after randomisation and provided no outcome data.
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FIGURE 3 Kaplan–Meier plot of time to ulcer healing by trial arm (unadjusted).
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Overall, these data do not provide evidence of a difference in time to healing with the addition of aspirin
to usual care. The placebo group tended to heal more rapidly but this difference is not statistically
significant. The numbers within this feasibility study are small and the results are inconclusive in terms of
the primary outcome.
Secondary outcomes
Adverse events
Six out of the 26 (23.1%) participants followed up had no reported AEs (placebo, n = 3; aspirin, n = 3)
and the remaining 20 had AEs (placebo, n = 9; aspirin, n = 11) (Table 8). The total number of events
experienced by participants was compared by trial arm adjusting for the prognostic factors (log of baseline
reference ulcer area and log of baseline reference ulcer duration) using negative binomial regression as per
the SAP. There was no evidence that participants receiving aspirin were more likely to suffer an AE than
those receiving placebo (incidence rate ratio 1.31, 95% CI 0.51 to 3.41; p = 0.58).
Serious adverse events
One participant suffered one SAE during the course of the study with the description ‘blood transfusion for
low Hb’ [haemoglobin]. This SAE was classified as expected and judged as severe in grade and probably
related to the blinded trial treatment (aspirin). This participant had 15 other non-serious AEs, of which two
subsequent events were thought to be related to the earlier SAE with descriptions ‘colonoscopy: colitis’
and ‘gastroscopy: stomach ulcer’.
Non-serious adverse events
There were 88 non-serious AEs (placebo, n = 36; aspirin, n = 52) recorded in total among 20 participants
(placebo, n = 9; aspirin, n = 11).
Ulcer-related pain
The mean baseline VAS score for ulcer-related pain was 37.7 (95% CI 22.0 to 53.4) in the placebo group
and was slightly higher at 45.4 (95% CI 24.6 to 66.2) in the aspirin group. At week 5, VAS scores had
reduced in both groups with the mean VAS score at week 5 at 13.3 (95% CI 0.3 to 26.3) in the placebo
group and 28.5 (95% CI 10.6 to 46.3) in the aspirin group (Table 9 and Figure 4).
TABLE 7 Healing of the reference ulcer (log-rank test, unadjusted and adjusted analysis)
Parameter HR (95% CI) p-value
Unadjusted Cox regression
Aspirin vs. placebo (allocation) 0.58 (0.19 to 1.72) 0.322
Adjusted Cox regression
Aspirin vs. placebo (allocation) 0.58 (0.18 to 1.85) 0.357
Area (log-transformed) 0.42 (0.22 to 0.81) 0.009
Duration (log-transformed) 0.61 (0.34 to 1.08) 0.089
df, degrees of freedom.
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Recurrence
Out of the 13 participants who healed, 12 (92.3%) were assessed for ulcer recurrence using the
recurrence assessment form (see Appendix 10, Form E), which was completed in the week 25 follow-up.
A recurrence was reported for two participants (placebo, n = 1; aspirin, n = 1). In both cases, the
participant was seen in clinic and the ulcer/wound site was clinically assessed. The time in days between
ulcer healing and recurrence for these two participants was 126 days (aspirin, healed at week 10) and
158 days (placebo, healed at week 3).
Time to first investigational medicinal product dose
Participants took their first dose of study drug a median of 4 days after randomisation (range 1 to 12 days)
(Table 10).
TABLE 8 Adverse events
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Overall (N= 26)
SAE, n 0 1 1
Number of participants with a SAE 0 (0.0) 1 (7.1) 1 (3.8)
Non-serious AEs, n 36 52 88
Number of participants with a non-serious AE 9 (75.0) 11 (78.6) 20 (76.9)
Relatedness of non-serious AE to treatment (blinded assessment)
Not related 21 (58.3) 30 (57.7) 51 (58.0)
Unlikely 1 (2.8) 0 (0) 1 (1.1)
Possibly 7 (19.4) 18 (34.6) 25 (28.4)
Probably 7 (19.4) 4 (7.7) 11 (12.5)
Definitely 0 (0) 0 (0) 0 (0)
Missing 0 (0) 0 (0) 0 (0)
Severity of non-serious AE (blinded assessment)
Mild 31 (86.1) 44 (84.6) 75 (85.3)
Moderate 3 (8.3) 4 (7.7) 7 (8.0)
Severe 2 (5.6) 4 (7.7) 6 (6.8)
Missing 0 (0) 0 (0) 0 (0)
Total 36 (100.0) 52 (100.0) 88 (100.0)
TABLE 9 Pain at baseline and follow-up
Pain VAS score Placebo Aspirin Overall
Baseline, n 13 14 27
Mean (95% CI) 37.7 (22.0 to 53.4) 45.4 (24.6 to 66.2) 41.7 (29.3 to 54.0)
Median (minimum, maximum) 30.0 (5.0, 80.0) 47.5 (0.0, 100.0) 35.0 (0.0, 100.0)
Week 5, n 12 13 25a
Mean (95% CI) 13.3 (0.3 to 26.3) 28.5 (10.6 to 46.3) 21.2 (10.4 to 32.0)
Median (minimum, maximum) 2.5 (0.0, 60.0) 20.0 (0.0, 75.0) 10.0 (0.0, 75.0)
a VAS score missing for two participants (placebo, n= 1; aspirin, n= 1) at week 5.
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Time of day
The time of day that participants generally took their IMP was recorded for 24 out of the 27 participants
randomised (88.9%; placebo, n = 11; aspirin, n = 13) (Table 11). The majority took the IMP in the morning
(70.8%; placebo, n = 9; aspirin, n = 8).
Ulcer area
Seven out of the 27 participants (26%; placebo, n= 3; aspirin, n= 4) had missing data for baseline ulcer area,
as measured by the analysis of a photograph, and so the measure that was calculated manually by the research
nurses was used instead for these participants. Photographs were not available for three measurements during
follow-up and so the area calculated from tracings was also used in these cases. Participants who healed
during the course of the study contributed to the computation of the ulcer area until healing or 2 weeks
after healing, according to the availability of an analysable photograph. Table 12 reports, by trial arm, the
number of participants with a valid measure of ulcer area, and the mean and the SD of the ulcer area for
each week. The mean ulcer area fluctuates more widely in the placebo group than in the aspirin group
(Figure 5) with a distinct fortnightly pattern. These fluctuations are caused by two participants who
attended their clinic appointments fortnightly and, coincidentally, in the same calendar weeks, and whose
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FIGURE 4 Plot of the mean VAS pain score at baseline and at week 5 by trial arm.
TABLE 10 Time to first dose (days)
Time to first dose (days) Placebo (n= 12) Aspirin (n= 14) Overall (n= 26)
Median (minimum, maximum) 3.0 (1.0, 7.0) 4.0 (3.0, 12.0) 4.0 (1.0, 12.0)
95% CI around median 2.0 to 7.0 4.0 to 7.0 3.0 to 6.0
TABLE 11 Time of day of first dose
Time of first dose
Group, n (%)
Placebo (N= 11) Aspirin (N= 13) Overall (N= 24)
Morning 9 (81.8) 8 (61.5) 17 (70.8)
Afternoon 0 (0) 3 (23.1) 3 (12.5)
Evening 2 (18.2) 2 (15.4) 4 (16.7)
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ulcer sizes were particularly large compared with those of the other participants in the placebo group. For
example, at baseline, the area of their ulcers was 168 cm2 and 129 cm2, while the mean of the ulcer area of
the other placebo participants at baseline was 19.1 cm2 (minimum of 2.14 cm2 and maximum of 78.0 cm2).
One of these two participants had an ulcer that was extended around the back of the leg, causing difficulties
in the estimation of the area. Figure 6 presents the mean ulcer area over time for the two groups, but with
the measurements from these two participants removed.
TABLE 12 Mean of ulcer area by visit week and allocation group
Visit week
Ulcer area (cm2)
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
n Mean (SD) n Mean (SD) n Mean (SD)
0 13 39.0 (53.1) 14 33.8 (37.1) 27 36.3 (44.7)
1 9 22.9 (31.2) 11 29.7 (25.4) 20 26.6 (27.6)
2 10 29.8 (43.5) 12 23.8 (19.2) 22 26.5 (31.9)
3 8 15.7 (12.8) 11 39.2 (42.6) 19 29.3 (34.9)
4 10 32.7 (48.4) 10 38.7 (38.9) 20 35.7 (42.8)
5 6 5.9 (7.0) 12 24.9 (24.2) 18 18.6 (21.9)
6 8 32.8 (52.3) 7 28.1 (25.9) 15 30.6 (40.8)
7 5 10.0 (6.9) 10 16.9 (18.6) 15 14.6 (15.7)
8 8 35.1 (53.4) 10 23.3 (14.5) 18 28.5 (36.4)
9 5 7.2 (7.5) 12 22.3 (16.7) 17 17.9 (16.0)
10 9 27.1 (43.8) 12 26.0 (24.9) 21 26.5 (33.3)
11 5 7.3 (7.9) 12 23.6 (24.6) 17 18.8 (22.1)
12 6 37.9 (51.3) 11 26.3 (22.3) 17 30.4 (34.1)
13 3 7.7 (9.5) 11 31.4 (31.0) 14 26.3 (29.3)
14 7 31.7 (42.8) 9 25.2 (22.5) 16 28.1 (31.8)
15 5 7.0 (8.1) 8 25.0 (18.9) 13 18.1 (17.7)
16 5 33.0 (37.1) 9 26.4 (18.6) 14 28.7 (25.5)
17 1 89.2 (.)a 8 37.5 (28.8) 9 43.2 (32.0)
18 4 24.2 (22.6) 8 25.8 (19.7) 12 25.2 (19.7)
19 3 14.2 (8.5) 5 27.6 (17.2) 8 22.6 (15.4)
20 4 41.0 (33.7) 6 26.7 (12.2) 10 32.4 (22.7)
21 2 11.5 (10.2) 6 44.8 (31.2) 8 36.5 (30.8)
22 4 39.4 (33.8) 6 22.5 (16.6) 10 29.2 (24.7)
23 2 10.9 (7.9) 7 29.1 (19.3) 9 25.0 (18.7)
24 3 34.9 (43.7) 7 27.3 (20.8) 10 29.6 (27.0)
25 2 12.2 (12.7) 7 33.0 (20.5) 9 28.4 (20.5)
26 0 – 0 – 0 –
27 0 – 1 4.8 (.)a 1 4.8 (.)a
a No estimate of SD, as data were only available for one participant.
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Compliance
Compliance with compression therapy
The mean number of visits attended up until healing or study exit was 13.3 (SD 7.3) and 17.4 (SD 6.8) in
the placebo and aspirin groups, respectively. Ten out of 12 participants (83.3%) in the placebo group and
10 out of 14 participants (71.4%) in the aspirin group were fully compliant with their compression therapy
(Table 13). Two participants in the placebo group (16.7%) and four participants in the aspirin group
(23.1%) were partially compliant. Reasons mentioned by participants for not complying with compression
were pain, slipping of the compression bandage, and the participant independently applying the compression
garment and, thus, not guaranteeing the correct level of compression. Two of the participants who were
classified as partially compliant, one in each group, declared full compliance in half of their visits, while the
other four participants did so for at least 89% of their visits.
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FIGURE 5 Mean of ulcer area and 95% CI for each week of follow-up stratified by allocation group
(lower confidence limits truncated at zero).
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FIGURE 6 Mean of ulcer area and 95% CI for each week of follow-up stratified by allocation group without the
two placebo group participants with rather extended ulcers (lower confidence limits truncated at zero).
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Compliance with AVURT capsules
The mean number of visits attended between the administration of the first dose and the date of healing
or study exit was 12.8 (SD 7.0) and 17.2 (SD 6.5) in the placebo and aspirin groups, respectively. The
imbalance between the groups is probably due to participants in the placebo group healing faster than
those in the aspirin group and, therefore, the number of visits in the placebo group is smaller than in
the aspirin group.
Eight out of the 12 participants (66.7%) in the placebo group were deemed fully compliant with AVURT
capsules and four (33.3%) were partially compliant (Table 14). In the aspirin group, 11 out of the
14 participants (78.6%) were deemed fully compliant and three (21.4%) were partially compliant. Among
the partially compliant participants, two in the placebo group and two in the aspirin group were fully
compliant for at least 88% of their visits. Reasons for not being fully compliant included illness, forgetting
to take the capsule and experiencing an AE. The other three participants (placebo, n = 2; aspirin, n = 1)
were deemed to be fully compliant for ≤ 54% of their visits. Two of these participants (placebo, n = 1;
aspirin, n = 1) were withdrawn from treatment at week 8 and week 14, respectively, while one participant
(in the placebo group) tended to forget to take the capsule.
Table 15 summarises the level of compliance with the study drug, as assessed by the returned pill count.
Ten participants in the placebo group (83.4%) and 10 participants in the aspirin group (71.5%) took at
least 90% of the AVURT capsules they should have taken.
Resource use
Resource use: compression therapy
All participants in the placebo group were prescribed high-level compression therapy (≥ 40 mmHg) at
baseline. In the aspirin group, 12 were prescribed with high-level compression and two with medium-level
compression (20–39 mmHg) (see Table 5).
TABLE 13 Compliance with compression therapy
Compliance with compression therapy
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Overall (N= 26)
Full compliance 10 (83.3) 10 (71.4) 20 (76.9)
Partial compliance 2 (16.7) 4 (28.6) 6 (23.1)
No compliance at all 0 (0) 0 (0) 0 (0)
Total 12 (100.0) 14 (100.0) 26 (100.0)
TABLE 14 Compliance with AVURT capsules
Compliance with AVURT capsules
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Overall (N= 26)
Full compliance 8 (66.7) 11 (78.6) 19 (73.1)
Partial compliance 4 (33.3) 3 (21.4) 7 (26.9)
No compliance at all 0 (0) 0 (0) 0 (0)
Total 12 (100.0) 14 (100.0) 26 (100.0)
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The total number of changes to the compression therapy prescribed at baseline during the study was 16,
with five changes (31.3%) to a medium compression level and nine changes (56.3%) to a high compression
level, one change (6.2%) to a low compression level and one change (6.2%) to no compression at all.
In the placebo group, four participants had their level of compression changed: two of them changed from
a high level of compression to a higher level, one changed from a medium level to a high level and the
fourth participant changed from a high level to a higher level, then to a medium level for 2 weeks and then
back to a high level. In the aspirin group, seven participants had their level of compression changed: two
participants changed from a high level to a higher level, two changed from a high level to a medium level,
one changed from a medium level to a high level, one started with a high level, changed to a medium
level for 1 week and then went back to a high level, and one went from a medium level to a low level for
2 weeks, then no compression for 10 weeks and after that back to a high level.
The maximum number of changes to level of compression therapy that a participant had during the
follow-up period was three (Table 16). Four out of the 12 participants in the placebo group (33.3%)
and seven in the aspirin group (50.0%) had at least one change to level of compression therapy; overall,
11 out of the 26 participants (42.3%) had at least one change during their follow-up. The highest number
of changes was seen in those participants staying in the study more than 4 months: four out of the six
changes (66.7%) in the placebo group and eight out of the 10 changes (80.0%) in the aspirin group were
prescribed to participants belonging to this group.
Resource use: compression therapy
Table 17 shows that during the follow-up period, a total of 25 changes to type of compression bandaging
were made, 11 (44.0%) in the placebo group and 14 (56.0%) in the aspirin group. Overall, the most
frequent changes were to other types of bandaging (32.0%), to three-layer bandaging (20.2%) and to
two-layer hosiery bandaging (16.0%).
The four-layer bandaging system was the most frequently used type of compression in this study (Table 18),
with 16 participants (59.3%) [eight in the placebo group (61.5%) and eight in the aspirin group (57.1%)]
receiving it at least once during their follow-up.
TABLE 15 Percentage of AVURT capsules actually taken of those that should have been taken
Percentage
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Total (N= 26)
100 4 (33.4) 6 (42.9) 10 (38.5)
90–99 6 (50.0) 4 (28.6) 10 (38.5)
80–89 1 (8.3) – 1 (3.8)
70–79 – 2 (14.3) 2 (7.8)
60–69 – 1 (7.1) 1 (3.8)
50–59 – – –
40–49 1 (8.3) – 1 (3.8)
30–39 – – –
20–29 – 1 (7.1) 1 (3.8)
10–19 – – –
0–9 – – –
Total 12 (100.0) 14 (100.0) 26 (100.0)
RESULTS
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TABLE 17 Number and percentage of changes to type of compression therapy
Compression bandaging
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Overall (N= 26)
Four layer 2 (18.2) 1 (7.1) 3 (12.0)
Three layer 2 (18.2) 3 (21.4) 5 (20.0)
Three-layer reduced compression 0 (0) 1 (7.1) 1 (4.0)
Reduced compression 1 (9.1) 0 (0) 1 (4.0)
Two-layer hosiery 2 (18.2) 2 (14.3) 4 (16.0)
Reduced compression hosiery 1 (9.1) 0 (0) 1 (4.0)
Othera 2 (18.2) 6 (43.0) 8 (32.0)
No bandaging 1 (9.1) 1 (7.1) 2 (8.0)
Total number of changes 11 (100.0) 14 (100.0) 25 (100.0)
a k-two layer high compression, actico compression bandaging, k lite k soft clinifast yellow line, juxta compression
garment.
TABLE 16 Number of participants per number of changes to compression therapy and period of healing or
censoring
Period of healing/censoring
(months)
Changes to compression therapy, n
Placebo (N= 12) Aspirin (N= 14) Total (N= 26)
0 1 2 3 0 1 2 3 0 1 2 3
0–2 2 2 0 0 0 0 0 0 2 2 0 0
2–4 2 0 0 0 4 2 0 0 6 2 0 0
> 4 4 1 0 1 3 3 1 1 7 4 1 2
Total 8 3 0 1 7 5 1 1 15 8 1 2
TABLE 18 Number and percentage of participants per type of bandaging received at least once
Compression bandaging received at
least once, n (%) Placebo (n= 13) Aspirin (n= 14) Overall (n= 27)
Four layer 8 (61.5) 8 (57.1) 16 (59.3)
Three layer 2 (15.4) 3 (21.4) 5 (18.5)
Three-layer reduced compression 0 (0) 2 (14.3) 2 (7.4)
Reduced compression 1 (7.7) 1 (7.1) 2 (7.4)
Two-layer hosiery 4 (30.8) 2 (14.3) 6 (22.2)
Reduced compression hosiery 1 (7.7) 0 (0) 1 (3.7)
Othera 6 (42.6) 7 (50.0) 13 (48.1)
No bandaging 1 (7.7) 1 (7.1) 2 (7.4)
a Some examples: class 11 stocking (40MM), k-two layer, actico, k lite k soft clinifast yellow line, juxta compression
garment, full compression 30 cm + ankle.
DOI: 10.3310/hta22550 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 55
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Tilbrook et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
Resource use: dressing
The mean number of changes to the type of primary dressing was higher in those participants with a longer
follow-up (> 4 months: mean 1.8, SD 2.0) than in participants with a shorter follow-up (≤ 4 months: mean
1.3, SD 1.5); Table 19). The mean number of changes to type of dressing per participant during the study
was 1.6 (SD 1.8) overall, 1.3 (SD 1.5) for the placebo group and 1.9 (SD 2.0) for the aspirin group.
A total of 41 changes to the primary dressing were recorded during the study (Table 20). A total of 15 out
of the 41 changes were in the placebo group (36.6%) while the remaining 26 were in the aspirin group
(63.4%). Overall, the most frequent changes were to silver-containing dressing (19.5%) and to basic
wound contact dressing (19.5%).
Table 21 shows that, overall, silver-containing dressings and basic wound contact were the most widely
used types of dressing in this study: 13 out of the 27 participants (48.1%) had a silver-containing dressing
at least once during their follow-up, five participants were in the placebo group (38.5%) and eight in the
aspirin group (57.1%); 11 participants (40.7%) had basic wound contact dressing at least once, six of
them were in the placebo group (46.2%) and five (35.7%) were in the aspirin group.
TABLE 19 Number of changes to primary dressing by period of healing or censoring
Number of changes by time period
Group
Placebo (n= 12) Aspirin (n= 14) Overall (n= 26)
0–2 months
Number of participants 4 0 4
Mean (SD) 1.5 (1.0) – 1.5 (1.0)
Median (minimum, maximum) 1.0 (1.0, 3.0) – 1.0 (1.0, 3.0)
IQR (25%, 75%) (1.0, 2.0) – (1.0, 2.0)
2–4 months
Number of participants 2 6 8
Mean (SD) 1.0 (1.4) 1.3 (2.0) 1.3 (1.8)
Median (minimum, maximum) 1.0 (0.0, 2.0) 0.5 (0.0, 5.0) 0.5 (0.0, 5.0)
IQR (25%, 75%) (0.0, 2.0) (0.0, 2.0) (0.0, 2.0)
> 4 months
Number of participants 6 8 14
Mean (SD) 1.2 (2.0) 2.3 (2.0) 1.8 (2.0)
Median (minimum, maximum) 0.0 (0.0, 5.0) 3.0 (0.0, 5.0) 1.0 (0.0, 5.0)
IQR (25%, 75%) (0.0, 2.0) (0.0, 3.5) (0.0, 3.0)
Whole study period
Number of participants 12 14 26
Mean (SD) 1.3 (1.5) 1.9 (2.0) 1.6 (1.8)
Median (minimum, maximum) 1.0 (0.0, 5.0) 1.5 (0.0, 5.0) 1.0 (0.0, 5.0)
IQR (25%, 75%) (0.0, 2.0) (0.0, 3.0) (0.0, 3.0)
RESULTS
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TABLE 20 Number and percentage of changes to type of dressing
Type of dressing
Group, n (%)
Placebo (N= 12) Aspirin (N= 14) Overall (N= 26)
Basic wound contact 3 (20.0) 5 (19.2) 8 (19.5)
Silver containing 1 (6.7) 7 (26.9) 8 (19.5)
Iodine containing 2 (13.3) 3 (11.5) 5 (12.2)
Hydrocolloid 2 (13.3) 1 (3.8) 3 (7.3)
Alginate 1 (6.7) 1 (3.8) 2 (4.9)
Soft polymer 0 (0) 2 (7.7) 2 (4.9)
Honey containing 0 (0) 1 (3.8) 1 (2.4)
Hydrogel 0 (0) 1 (3.8) 1 (2.4)
Foam 1 (6.7) 0 (0) 1 (2.4)
Film 0 (0) 0 (0) 0 (0)
Other antimicrobial dressinga 0 (0) 1 (3.8) 1 (2.4)
Otherb 2 (13.3) 2 (7.7) 4 (9.8)
No dressing 3 (20.0) 2 (7.7) 5 (12.2)
Total 15 (100.0) 26 (100.0) 41 (100.0)
a Suprasorb + PHMB (polyhexamethylene biguanide) – antimicrobial hydrobalance, cutimed sorbact.
b Promogran, clinisorb, suprasorb X, suprasorb X + PHMB + duodery extra thin hydrocolloid dressing around the edge of
the ulcer.
TABLE 21 Number and percentage of participants per type of dressing received at least once
Type of dressing received at least once
Group, n (%)
Placebo (N= 13) Aspirin (N= 14) Overall (N= 27)
Silver containing 5 (38.5) 8 (57.1) 13 (48.1)
Basic wound contact 6 (46.2) 5 (35.7) 11 (40.7)
Iodine containing 3 (23.1) 5 (35.7) 8 (29.6)
Hydrocolloid 1 (7.7) 3 (21.4) 4 (14.8)
Alginate 2 (15.4) 1 (7.1) 3 (11.1)
Honey containing 0 (0) 2 (14.3) 2 (7.4)
Soft polymer 1 (7.7) 1 (7.1) 2 (7.4)
Hydrogel 0 (0) 1 (7.1) 1 (3.7)
Foam 1 (7.7) 0 (0) 1 (3.7)
Film 0 (0) 0 (0) 0 (0)
Other antimicrobial dressinga 1 (7.7) 1 (7.1) 1 (3.7)
Otherb 1 (7.7) 2 (14.3) 3 (11.1)
No dressing 4 (30.8) 4 (28.6) 8 (29.6)
a Suprasorb + PHMB (polyhexamethylene biguanide) – antimicrobial hydrobalance, cutimed sorbact.
b Promogran, clinisorb, suprasorb X, suprasorb X + PHMB + duodery extra thin hydrocolloid dressing around the edge of
the ulcer.
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Resource use: wound consultations
The mean number of wound consultations per week was 2.1 (SD 1.4) in the placebo group, 1.9 (SD 0.7)
in the aspirin group, and 2.0 (SD 1.0) overall (Table 22).
Protocol violations or issues that may have an impact on analysis
One participant was unblinded after the trial had completed treatment and analysis was being undertaken.
The participant was unblinded via the emergency unblinding procedure after consultation and agreement
with the Independent Steering Committees and DMCs. At the time of writing, the TMG has remained
blind to this participant’s allocation.
No protocol violations were reported.
TABLE 22 Mean number of wound consultations per week
Number of wound consultations
per week
Group
Placebo (n= 12) Aspirin (n= 14) Overall (n= 26)
Mean (SD) 2.1 (1.4) 1.9 (0.7) 2.0 (1.0)
Median (minimum, maximum) 1.9 (1.0, 5.7) 1.9 (1.0, 3.5) 1.9 (1.0, 5.7)
IQR (25%, 75%) (1.1, 2.0) (1.6, 2.0) (1.3, 2.0)
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
Chapter 5 Discussion
This pilot trial, in which feasibility of recruitment was one of the objectives, was only able to recruit 27%of its target sample size but has important findings for informing the trial design of future CTIMP
studies for this patient population.
Summary of findings
Owing to under-recruitment, we were unable to confirm the efficacy of aspirin for VLU healing.
Recruitment was more difficult than anticipated owing to the large number of patients already prescribed
aspirin medication, predominantly for cardiovascular risk factor management, or who were on concomitant
antiplatelet therapies. Others were excluded because they had contraindications to aspirin therapy, had
small ulcers of ≤ 1 cm2 (that were anticipated to heal rapidly) or did not want to be enrolled (frequently
reported to be associated with the need for regular clinic attendance).
Participants included in the trial had ulcers of a significantly long duration and may have been considered
more difficult to heal. The ulcers that most participants had were large, with 80% of them having a
surface area of > 5 cm2.
The relatively small number of participants recruited to the trial means that any data should be interpreted
with caution. There were a large number of AEs during the trial (n = 89) with most participants (77%)
suffering at least one. The majority of these AEs were non-serious (n = 88) and among these 51 (58%)
were not related to aspirin. However, there was one SAE of gastrointestinal bleeding requiring blood
transfusion. Aspirin was generally well tolerated and there was no evidence of a difference in the number
of experienced AEs in the two trial arms.
Compliance with the medication was good, with nearly three-quarters of participants being fully compliant
and one-quarter partially compliant. Similarly, the compliance to compression therapy was very good
overall and was similar between the treatment groups.
Before study commencement, a decision was made not to collect any data on health-related quality of life
and collect only limited resource use health economic data. This was for reasons of brevity and the focus
of the trial being feasibility. However, it was hypothesised that participants may receive some benefit in
terms of pain relief if they received 300 mg of aspirin daily. The self-reported pain scores at 5 weeks
showed no evidence that participants in the aspirin group suffered less pain. The number of clinic visits
and dressing/compression changes were also similar among the groups.
The patients taking part in the study tended to have a high BMI, some were experiencing a high degree of
ulcer-related pain and the majority receiving high-compression bandaging. A few months into recruitment,
and finding that many of the patients were not meeting the trial criteria, we explored recruitment from
primary care, which involved a limited database search of records held in primary care. However, very few
patients were identified as there were limitations associated with conducting the search on the trial’s eligibility
criteria. There may have been potentially eligible patients being treated by nurses in general practices. Further
investigation of recruitment from primary care was not undertaken owing to time and budget constraints.
Limitations
There are a number of limitations of the trial. Because the trial under recruited (by 73%), some of the
pre-planned analyses were infeasible or inappropriate. Because of the low number of participants, for
example, the shared centre frailty effects could not be tested and the repeated measures mixed model
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for ulcer area could not be estimated. In these cases, the most appropriate analyses were performed.
Information concerning compliance with both medication and compression therapy was obtained by
participant self-report and pill count.
At the outset of the trial the sponsor did not enforce recruiting sites to record pre-screening log data owing
to the disparate nature of the clinics seeing and recruiting patients. It was felt by the sponsor that the
heterogeneous nature of the clinics and, therefore, patients would render a pre-screening log meaningless.
For example, one site, at St George’s, offered a complex wound service led by a vascular surgeon (high
prevalence of PAD and very chronic wounds). In contrast, other sites, such as the one in Brighton, were
effectively based in the community with a large number of patients with very small and less complex ulcers
that were managed solely by nurses. This omission was rectified later but, consequently, the pre-screening
data reported is an under-representation of the number of patients screened. It was not possible to conduct
second checks of the pre-screening data and there is the possibility of duplicate and incomplete entries.
In addition, the data should be interpreted with caution owing to major differences among demographics
between some of the recruiting sites.
It is worth reflecting that the relative rates of healing in this study are very far removed from those seen
in the earlier UK and Spanish studies,25,26 which prompted this call for research. One explanation for this
may have been the much larger ulcers in this trial or, perhaps, their more chronic nature.
Strengths
Retention and follow-up rates were high and there were few missing data. Both the trial coapplicants
and the REC were concerned that participants may suffer a significant number of aspirin-related AEs and
SAEs, but this did not appear to be the case. In fact, the number of related events was quite low and the
medication appeared to be well tolerated. The frequency of follow-up, once weekly or fortnightly, was to
ensure, in part, that information on AEs was identified early (perhaps before progression to more serious
AEs). It is possible that some participants suffered other AEs that were related to aspirin, but this seems
unlikely given the frequency of assessment.
The aspirin and placebo were manufactured and over-encapsulated effectively in a large capsule. There
were some concerns that this may affect participant compliance. However, the sponsor’s previous experience
with IMP manufacturer and capsule size was reassuring. Indeed, in this trial participant compliance with
medication was generally very good and non-compliance was not associated with the size of the capsule.
Data were captured on ulcer area using two formats: paper tracings and digital image analysis. Both of
these techniques are supported by published data3,44 on their reliability and have been used extensively in
clinical trials previously. We also decided to use digital image analysis as we thought it may prove easier
for the nursing staff. However, many nurses felt more comfortable with wound tracing, especially with the
larger ulcers, which may be more difficult to capture in a two-dimensional digital photograph. At the most
important time points (baseline and completion of the study), wound tracings were taken to avoid any
problems associated with two-dimensional image analysis.
Interpretations
Owing to under-recruitment, we were unable to confirm the effect sizes found in two other published
studies, and reliably and confidently establish the safety of aspirin in this population.
It may have been possible to recruit more patients to the trial if other centres could have been rapidly
involved. However, the very short nature of the trial meant that it was impossible to involve other centres
in a timely fashion.
DISCUSSION
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Generalisability/contribution of this study to the evidence
AVURT was based on plausible results from two other studies investigating aspirin for VLUs.25,26 This trial
has demonstrated that it was possible to randomise those participants who could be recruited, but the
study clearly demonstrated that it was not feasible to recruit the necessary participants in the context of a
RCT in the UK.
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Chapter 6 Conclusions
AVURT was a Phase II randomised pilot trial of aspirin versus placebo for the treatment of patients withchronic venous leg ulceration. It was not possible to recruit the planned number of patients despite an
unfunded extension to the trial and, therefore, it can be concluded that a larger Phase III (effectiveness)
trial would not be feasible. A future trial would need many centres over a long period of time to get the
required numbers if there were no modifications to the inclusion and exclusion criteria.
The Health Technology Assessment (HTA) programme reviewed progress on the study in January 2016 and
advised that, in view of the recruitment difficulties that this pilot trial had experienced and was continuing
to experience, they did not think it was feasible to recruit the target sample size by the end of July 2016
(the last possible date that participants could be recruited owing to IMP expiry) and, therefore, would not
support a funded extension.
There were a number of reasons why patients were excluded or unsuitable for the trial. These included
patients with small ulcers at screening and concomitant aspirin therapy (or other concomitant medical
therapies that were exclusion criteria). Small ulcers were excluded from the trial because these heal rapidly
and the effect of aspirin was unlikely to significantly improve outcome (with potentially increased risks).
In retrospect, it may have been possible to randomise patients who were taking 75 mg of aspirin to the
larger dose of 300 mg that was used in the trial. However, there are no data (from biological plausibility
studies or small trials) to suggest that taking a larger dose of aspirin may have proven effective.
There was a large number of patients already taking aspirin or other antiplatelet medications at screening
for cardiovascular indications. It seems likely that this proportion will increase in the future with an ageing
population. This suggests that it will likely prove increasingly difficult in the future to recruit to trials of
aspirin in patients with chronic venous ulcer of the leg, even if significant changes were made to the
present trial design.
The centres recruiting in this trial were identified because they expressed an interest in the trial,
estimated that they would be able to recruit sufficient numbers and were the highest recruiters to a
previous chronic VLU trial funded by NIHR HTA run through the YTU. The majority of these centres were
in a clinic setting (mainly in secondary care locations). It is possible that patients with chronic VLUs are,
perhaps increasingly, managed in primary care or in the community. It is also quite possible that younger
or fitter patients with easier-to-manage chronic VLUs who may have been eligible for this trial (as they
are more likely to have fewer contraindications) were more likely to be managed in the community.
Attempts were made to explore recruitment from primary care but this was limited given the relatively
short duration of the trial. It is recommended that future studies consider rigorous pre-screening in
the design stage of the trial to obtain realistic numbers of potentially eligible patients and to inform
recruitment strategy.
Overall, sites found this trial very difficult to recruit to, despite suggesting to the contrary when originally
approached. The narrow recruitment window and overall short duration of the trial made it impossible to
make changes to the trial recruitment strategies to meet that challenge. The trial’s DMC and TSC both
requested that it was reported that the commissioned call for AVURT did not allow sufficient time for the
trial to be performed. A 6-month recruitment period was not long enough.
AVURT was designed to very carefully identify AEs. The trial applicants and REC were both concerned
that AEs may go unnoticed (e.g. mild gastrointestinal side effects leading to potentially life-threatening
complications). There were a large number of AEs in the trial, but most were unrelated to the IMP and
only one was serious. The overall safety of 300 mg of aspirin once daily in this group of participants would
appear to be reasonable (and when a SAE was noted, it was pre-dated by milder gastrointestinal symptoms).
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Given these observations, it would appear reasonable to suggest that any further trial of aspirin intervention
in chronic VLU might be possible to be performed with fewer clinic visits.
The intervention itself (300 mg of aspirin) appeared feasible and safe in this population but a Phase III RCT
would not appear to be feasible in the UK in a hospital clinic-based setting.
CONCLUSIONS
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Appendix 1 Recruiting sites
Site ID Site Sources of recruitment
Date open to
recruitment Target
Participants
recruited
14 Freeman Hospital,
Newcastle upon Tyne
Hospital outpatients within
vascular attended by
vascular nurses and specialist
vascular nurses
23 June 2015 5 3
11 St John’s Therapy Centre,
London
Hospital outpatient clinic
attended by community
tissue viability nurses
6 July 2015 12 7
21 Sussex Community NHS
Trust, Brighton General
Hospital, Brighton
Community leg ulcer clinic 9 July 2015 6 2
17 Hull Royal Infirmary, Hull Hospital outpatient leg ulcer
clinic
10 July 2015 8 6
18 Harrogate District NHS
Trust, Harrogate
Hospital outpatient leg ulcer
clinic
23 July 2015 4 2
24 Kent Community Health
NHS Trust
Wound medicine centres
(set-up to treat ambulant
patients with long term
wounds). Centres overseen
by tissue viability nurses
28 September 2015 10 3
22 Monklands Hospital,
Lanarkshire
Hospital outpatient leg ulcer
clinic
9 October 2015 10 1
15 Wound Healing Research
Unit, Cardiff University,
Cardiff
General research clinic for
wounds within the university
14 October 2015 15–30 0
23 Ninewells Hospital &
Medical School, Dundee
Primary care leg ulcer clinic 4 November 2015 5–11 0
20 Lancashire Care NHS
Foundation Trust
Community nursing case
loads
11 November 2015 4 3
Total 79–100 27
DOI: 10.3310/hta22550 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 55
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Tilbrook et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55

Appendix 2 Pre-trial screening forms
DOI: 10.3310/hta22550 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 55
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Tilbrook et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
A
PPEN
D
IX
2
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
58
D
O
I:10.3310/hta22550
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.55
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
Tilbrook
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
59

Appendix 3 Patient information sheet
[Insert Trust/site logo] 
INFORMATION SHEET 
Study Title: AVURT: Aspirin for Venous Ulcers Randomised Trial 
Chief Investigator: Mr Robert Hinchliffe, 
Reader and Honorary Consultant in Vascular Surgery 
Invitation to take part in a study: 
We would like to invite you to take part in a research study. Before you decide we 
would like you to understand why the research is being done and what it will 
involve for you. Please take time to read this information carefully and discuss it 
with others if you wish. We wil l  go through the information sheet with 
you and answer any questions you have. This should take about 15-20 
minutes. 
Part 1 of the information sheet tells you the purpose of this study and what will 
happen to you if you take part. 
Part 2 gives you more detailed information about the study. 
Please ask us if there is anything that is not clear. Take time to decide whether or 
not you wish to take part. 
Part 1 – The purpose of the study and what will happen to you if you 
take part.  
What is the purpose of the AVURT study? 
Compression (leg bandaging or surgical stockings) therapy is the main treatment for 
venous leg ulcers. However it can be both uncomfortable and inconvenient for 
everyday life and ulcers may take many months to heal. There is some evidence that 
taking daily (300mg) aspirin, in addition to compression therapy might improve the 
healing of venous leg ulcers. But we are not sure that this is true, so further research 
is required. 
AVURT, 
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[Insert Trust/site logo] 
Aspirin is not currently given routinely to patients for leg ulcers, but is commonly used 
for other conditions and is a cheap drug with relatively few side effects. 
In this small study we want to test whether aspirin is better than placebo (dummy 
medicine) at improving the healing of venous leg ulcers, and if it is safe to use in 
people with venous leg ulcers. We wish to include 100 patients in the study. If our 
study shows that taking aspirin could be beneficial we may then decide it is 
worthwhile carrying out a larger study. 
Why have I been invited to take part? 
We are inviting patients who have a venous leg ulcer that has been present for more 
than six weeks, and is larger than 1cm2, to take part in the study. You will have been 
invited to take part by a member of your usual medical team or a member of the 
research team who will also discuss with you what is involved in taking part. 
Do I have to take part? 
No, it is up to you to decide whether or not to take part. If you do, you will be given 
this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw from the study at any time and without giving a reason. A decision not to 
take part, or to withdraw at any time, will not affect the standard of care you receive 
now or in the future. 
What will happen to me if I take part? 
If you choose to take part in the study and sign a consent form: 
• You will have information collected about you to confirm that you are suitable 
for the study. 
• You will have your medical history and any medications you are currently taking 
recorded. A nurse may also ask you to bring in a copy of your prescriptions if you 
have any. 
• It may be necessary for a nurse or the doctor prescribing your study medication 
to contact your GP to obtain details to check whether you are suitable for the 
AVURT, 
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[Insert Trust/site logo] 
study. The study doctor may also need to phone you to check your 
medical history and ask about medications. 
• If you are suitable to take part in the study, you will be given either aspirin 
or a placebo treatment by chance like the flipping of a coin. 
• The study medication can be posted to your home or you can collect it from 
the clinic depending on what is best for you. 
• You will have your leg ulcer photographed in order to measure its size at the 
beginning, as well as during your normal weekly visits to clinic or during home 
visits over a period of 25 weeks from when you enter the study. If you have more 
than one leg ulcer, we shall only take a photo of the largest ulcer. In addition you 
will have a tracing of your ulcer done at the beginning of the study. If 
photographs cannot be taken then a tracing of the ulcer will be made instead. 
• When you get your aspirin or placebo you will be asked to take it once a day 
for a maximum of 24 weeks. The study medication should be taken with or 
after food. 
• You will be asked about the following during your routine weekly visits: any 
change to other medications you are taking, such as if you have stopped or 
have had a medication dose change; whether you have been able to take the 
trial medication every day as prescribed; and, any change in your health since 
the previous visit such as headaches or indigestion. If you are male, you will 
be asked if your partner has become pregnant. 
• Your usual nurse or a research nurse will check the size of your ulcer and its 
healing during the weekly visits. 
• If your ulcer has not healed you will also have it traced during your clinic visit 
or home visit in week 25. 
• If your ulcer has healed, you will receive a follow up phone call from your 
clinic, in week 25, to check if the ulcer has returned. 
• During your first and fifth treatment visits you will be asked about the amount 
of pain you are having from your venous leg ulcer. 
AVURT, 
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[Insert Trust/site logo] 
• Your nurse will advise you to stop taking the study medication if your ulcer is 
confirmed as healed, or if you experience any problems which could be due to 
the study medication. 
• Your participation in the trial will be for 25 weeks unless your ulcer looks like it 
has healed in week 24 or 25. If this is the case, we would like you to continue 
in the study for a further two weeks so that we can take weekly photographs of 
the ulcer, and ask about changes to your medications and to your health since 
your last visit. 
• Your participation in the trial will be for a maximum of 27 weeks. 
What do I  have to do? 
The study will last for 6 months and we want you to: 
• Attend your usual leg ulcer clinic regularly /once a week or receive treatment 
at home as you normally do. If you are unable to attend the clinic or are not 
seen for a home visit for three consecutive weeks a nurse will phone you to 
ask about how you have been feeling and about taking the study medication. 
• Men and pre-menopausal women will need to use an effective method of birth 
control (either hormonal in the form of the contraceptive pill or barrier method 
of birth control accompanied by use of a proprietary spermicidal foam/gel or 
film; or agree to true abstinence (i.e. withdrawal, calendar, ovulation, and post 
ovulation are not acceptable methods) from time of consent until 6 weeks 
after the last dose of the trial medication. 
• The study medication can be posted to your home or you can collect it from 
the clinic depending on what is best for you. If the study medication is posted 
to your home, we will need you to phone the pharmacy on  
as soon as possible to let them know you have received it. 
• Take the study medication (aspirin or placebo) once a day, with or after food, 
for a maximum of 24 weeks. If your leg ulcer is confirmed as healed before 
the end of 24 weeks, you will be asked by a member of your medical team to 
stop taking the medication 
• Continue with any other treatment your medical team advises. 
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• Complete the study questionnaire at the first visit, around 4 weeks later and 
one at the end of the study. The questionnaire is very short and the research 
nurse will help you. 
• Provide a pain score at your first visit and 5 weeks after you have started in 
the study (approximately 4 weeks after receiving your study medication). 
• Keep a diary of any changes in any other medication throughout the trial 
and/or bring in prescriptions on a regular basis. 
• Provide information about how you have been feeling especially if you have 
felt unwell. 
• You will also be given a 24 hour contact card with the details of St George's 
Research Pharmacy. If you feel unwell and require urgent treatment you 
should use your local NHS services and take the card with you so that a health 
professional can use it if they need to know which treatment you are receiving 
in the study. 
• If your leg ulcer heals during the study, we will give you a card and a stamped 
addressed envelope for you to notify the research team if the ulcer breaks 
down again. 
• Return your study medication container and any remaining study medication 
to the clinic at the end of your participation in the study (25 weeks after you 
entered the study) or earlier if requested by the research team. If the 
community nurse visits you at your home please ensure the study medication 
bottle (complete with intact label) is handed over. The bottle will be returned 
to the Research Pharmacy at St George’s Hospital. 
What treatment will I get? 
Sometimes we don’t know which way of treating patients is best. To find out, we need 
to compare different treatments. We put people into groups and give each group a 
different treatment. The results are compared to see if one is better. To try to make 
sure the groups are the same to start with, each patient is put into a group by chance  
(like flipping a coin). You will get one of two treatments. 
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Group 1 Aspirin 300mg capsules; Group 2 Placebo capsules. 
One capsule to be taken once every day for a maximum of 24 weeks. The capsule 
should be taken with or after food. You will be asked to stop taking your study 
medication before the end of 24 weeks if your leg ulcer is confirmed as healed. 
Swallow the capsules whole- do not crush or chew. The amount of aspirin is the size 
of a tablet you might take for a headache. 
You will have an equal chance of receiving aspirin or placebo. Neither you, your 
health care team treating your ulcer or your doctor will know which treatment you are 
receiving. However, if your doctor needs to find out they can do so. 
What are the alternatives for treatment? 
The usual option available to you is compression therapy using bandage components or 
layers wrapped around the leg, or compression hosiery (for example compression 
stockings). In some cases venous (varicose vein) surgery may be performed. However 
these options can be uncomfortable, inconvenient for everyday life and take patients 
many months to heal. In this study we aim to find out if adding daily (300mg) aspirin to 
compression therapy might improve the healing of venous leg ulcers. 
What are the possible benefits of taking part in this study? 
If you do take part, you will be contributing to our knowledge about how best to help 
people with chronic venous leg ulcers. We cannot promise the study will definitely help 
you as an individual, but we hope that the information and knowledge we get from this 
study will help improve the treatment of people with venous leg ulcers. If our idea that 
the addition of aspirin to standard therapy does work, then you could potentially benefit 
by your ulcer healing faster. 
What are the possible disadvantages and risks of taking part? 
• You may consider completion of study assessments and taking daily medication 
as inconvenient. 
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• There are some medications that should not be taken with aspirin. There are also 
medications that require caution when taking aspirin. A nurse will ask about any 
medications you are currently taking before you start participating in the study, as 
well as frequently (approximately once a week) during study participation. It is 
important to let your nurse know about the other medications you are taking; and 
also to let your doctor or pharmacist know that you are taking aspirin when you 
get new prescriptions or buy other medications from your pharmacy including 
herbal and complementary medicines. 
• Aspirin is not suitable for people with certain conditions, and sometimes a medicine 
may only be used if extra care is taken. For these reasons, it is important that your 
doctor and the research team know of any other medical conditions you might have. 
Your doctors and research team will check carefully that any other medical 
conditions you might have should not provide cause for concern. 
• If you are pregnant or breastfeeding, considering pregnancy or are not taking 
adequate contraception you will not be able to take part in this study. For women 
t is also important during the study to let your doctor and the research team know 
if you get pregnant, or are trying for a baby. If you become pregnant during this 
study, then you should stop taking the trial medication immediately. If you or your 
partner becomes pregnant during the course of the study we will then need to ask 
you questions about your, your partner’s health and your unborn child’s health 
until your baby is born. 
• Also tell your doctor and the research team if you have ever had an unusual or 
allergic-type reaction after taking aspirin or a non-steroidal anti-inflammatory drug 
(NSAID). NSAIDs include ibuprofen, diclofenac, indomethacin and naproxen. 
• You must not take any other preparation which contains aspirin, or any non-
steroidal anti-inflammatory painkiller without first seeking the advice of a 
healthcare professional such as a pharmacist or GP. 
• You will not be able to participate in this study if you are currently participating in 
another study evaluating leg ulcer therapies. 
What are the possible side effects of Aspirin? 
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Aspirin is generally safe and most people do not have any problems. But like all 
medicines, it can cause problems among some people. Aspirin has been used for many 
years and the problems with aspirin are well known to healthcare professionals. We will 
check regularly about the known problems. 
• The common problems include: feeling sick, indigestion and increased risk of 
bleeding (for example, an increase in the number of nose bleeds, longer bleeding 
time or bruising more easily). If  you notice any of these problems tell  
your doctor or nurse. 
• Other problems include the following: difficulty breathing, stomach irritation, 
stomach ulcers or bleeding which can be severe (you may develop bloody or black 
tarry stools, severe stomach pain and vomit blood). Inflammation of the liver 
causing yellowing of the skin or eyes or tiredness, pain in abdomen, joint or 
muscles may also occur. If  you experience any of these problems STOP 
taking this medicine and contact a doctor immediately. 
• Aspirin can also cause allergic reactions which may present as blistered skin, 
swelling of the face, lips, throat or tongue, difficulty breathing, worsening of 
asthma, shock. There may also be severe rash involving reddening, peeling and 
swelling of the skin that resembles severe burns; or severe rash, blisters, or red 
patches on the skin. If  you experience any of these problems STOP 
taking this medicine and contact your doctor immediately. 
Speak to your doctor or nurse for advice if you experience any other symptoms which 
you think may be due to your study medication. In this study aspirin is being given for 
the healing of venous leg ulcers, and not for pain, cardiovascular or other conditions. 
Will taking part in this study cost me anything, and will I be paid? 
Participation in this study should not cost you anything and there will not be any 
payment for taking part. 
Will my taking part in the study be kept confidential? 
Yes, we will follow ethical and legal practice. All identifiable information that is collected 
about you during this study will be kept confidential and secure, disclosed only to 
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authorised persons such as researchers, the sponsors (St George’s University of 
London representatives),and regulatory authorities (for the monitoring of the quality 
and safety of the research). Access to your medical records may also be required for 
this purpose. 
Your name or other directly identifiable information will not appear on any materials 
produced from this study. You will only be known by a unique trial identification number 
that will be used on all information collected about you for the purposes of the study. The 
reports of the research findings may also include anonymised venous leg ulcer 
photographs from participants who have given permission for their photographs to be 
used in this way. 
Your consent form and questionnaires will be stored confidentially and securely at 
the clinic you attend. Copies of your trial questionnaires and photos will be sent 
securely to the University of York’s Trials Unit that will be processing the emerging 
study information. The questionnaires and photos will only include your unique trial 
identification number and will not contain your name. 
Study information sent to the University of York will be held there for a minimum period 
of 12 month after the end of the study. Following this time period the study information 
may be transferred to St George’s University of London for long term storage. 
Will my GP be told of my participation in this study? 
Yes, if you agree to take part in this study we will tell your GP. We may also contact your 
GP about your health when this is necessary during the study. 
What happens when the study stops? 
You will not be provided with any further study medication once your study participation 
ends. You will however continue to receive your usual treatment in the normal way. 
Part 2- More detailed information about the conduct of the study. 
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What if relevant new information becomes available? 
If we get new information about the study medication during the study a research 
doctor or nurse will tell you and discuss whether you should continue in the study. If 
you decide not to carry on, your care will be continued outside of the study. If you 
decide to continue in the study you will be asked to sign an updated consent form. 
If your research doctor or nurse considers you should not carry on with the study they 
will explain the reasons to you. If the study is stopped for any other reason, we will 
tell you. In both situations your care will be continued outside of the study. 
What will happen if I don’t want to carry on with this study? 
Participation in the study is voluntary. You can choose to withdraw from the study at 
any time. 
You may wish to withdraw from the treatment, but continue with the study follow up 
visits and assessments. 
If you choose to also discontinue the follow up visits and assessments, with your 
permission, we will keep the information that has been collected already but would 
not collect any more. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer all your questions: contact [Insert 
names of trial co-ordinators and CI and their contact numbers] 
If you wish to complain, or have any concerns about how the study is being carried 
out, or any other aspects of your care, you may contact: 
[ INSERT LOCAL INFORMATION, FOR EXAMPLE THE PATIENT ADVICE 
AND LIAISON SERVICE CONTACT N FORMATION] 
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The normal National Health Service complaints mechanisms are also available to you. 
If you are still not satisfied with the response, you may contact the Sponsor 
representative at St Georges University of London: [Insert name and contact number] 
St Georges, University of London has agreed that if you are harmed as a result of your 
participation in the study, you will be compensated, provided that, on the balance of 
probabilities, an injury was caused as a direct result of the intervention or procedures 
you received during the course of the study. These special compensation arrangements 
apply where an injury is caused to you that would not have occurred if you were not in 
the trial. We would not be bound to pay compensation where: The injury resulted from a 
drug or procedure outside the trial protocol and/or the protocol was not followed. These 
arrangements do not affect your right to pursue a claim through legal action. 
What will happen to the results of the research study? 
The results of this study may be published in journals or presented at scientific 
meetings so other doctors or nurses caring for similar patients can learn from your 
experience. However, you will not be identified in any reports, publications or 
presentations. A summary of the results of the study can be sent to you if you like. 
Anonymised data that you provide may be used by authorised researchers studying 
other relevant research projects. Please let us know if you do not agree to this. 
Who is organising and funding the research? 
St Georges, University of London is the study Sponsor and is taking the overall legal 
responsibility for the study and will undertake the monitoring and oversight of the 
participating sites. The study has received funds awarded by the NHS National 
Institute for Health Research, Health Technology Assessment Programme [grant 
number NIHR HTA: 13/87/08] 
The research team is led by Mr Robert Hinchliffe, Reader in Vascular Sciences and 
Honorary Consultant in Vascular Surgery, St George’s Vascular Institute, St George’s 
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University of London and St George’s Healthcare NHS Trust. The trial is managed 
by the York Trials Unit at the University of York. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee (REC), to protect your interests. This study has been 
reviewed and approved by [Insert name here] Research Ethics Committee. It has 
also been reviewed by your local hospital Trust Research and Development 
Department. 
Further Information and Contact Details 
If you require further information about this study you can contact the following: 
Trial Co-ordinators: [Insert names and contact numbers] 
Sponsor Representative: [Insert name and contact number] 
If you are unhappy with any aspect of this study, or have any concerns please 
contact: 
Trial Co-ordinators: [Insert names and contact numbers], or 
Chief Investigator: [Insert name and contact number] 
Call the following number Monday – Friday 09:00hrs – 17:25hrs to let the 
pharmacy know you have received your AVURT study medication: [Insert contact 
number] 
Other useful contact numbers 
Your Research Nurse or Nurse 
Name: [Insert site contact details] 
Tel. Number: [Insert site contact details] 
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Appendix 5 Screening form
Site ID:                           Screening ID:                                                      Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 1 of 8 
AVURT 
 
Aspirin for Venous Ulcers: Randomised Trial  
 
Screening  
For Study Investigator Completion 
Before completing this form please ensure that the patient has 
signed the consent form indicating their willingness to take part in 
the trial 
I am confident that this information is accurate and complete and I can confirm that the study is being conducted 
according to protocol and any subsequent amendments and that consent was obtained prior to study entry. Please 
sign this after the CRF has been completed in full  
     Signed_______________________________ (Site Principal Investigator) 
     
     Print___________________________________    Date signed (DD/MM/YY) 
 
                                            
 
Date informed consent obtained   (DD/MM/YY)           
When completed please fax to York Trials Unit on: 
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Site ID:                    Screening ID:                                                  Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 2 of 8 
 
Instructions for this questionnaire 
 
The following questionnaire contains a series of questions designed to screen 
patients for participation in the AVURT trial. 
 
Informed consent MUST be obtained prior to any screening procedure, including the 
completion of this form.  
 
This CRF may be completed by the principal investigator or a delegated member of 
staff listed on the AVURT Delegation Log. However the details on this form and the 
eligibility of the patient must be confirmed by the delegated doctor who must sign 
and date Section G3 of this form and provide their details. 
 
Please complete all sections of the form using the spaces provided and only skip 
sections if the text directs you to do so.  
 
If the patient is eligible ensure a medically qualified Doctor checks and signs off 
section G prior to proceeding to AVURT prescribing and randomisation. 
 
 
If you have further questions please contact a member of the York Trials Unit whose 
details you will find in the AVURT site information file.  
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Site ID:                      Screening ID:                                                     Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 3 of 8 
Section A: Demographic Data  
 
PERSONAL DETAILS OF PATIENT 
 
1.   Date of birth              DD                          MM                          YY                                                                                                  
 
                                
 
2.  Gender     Male                        Female  
 
 
3. Has the patient ever smoked?           Never         Current smoker       Previous smoker  
 
 
 
SECTION B: Assessment of child bearing potential for MALE and FEMALE participants 
 
 
1. Is the patient (male or female) of child bearing potential?   Yes                No 
 
 
 
 
 
 
 
If NO please proceed to Section D 
2. If YES does the participant agree to use a reliable method of contraception* for the duration 
of the study and a further six weeks after the last dose of study medication?                               
Yes             No              
*Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable 
hormonal method, intrauterine devices or barrier contraceptives   
If NO the patient is ineligible for participation in AVURT. Please proceed directly to section F and 
complete  
- If YES and Male please proceed straight to section D 
-  If Yes and Female continue to section C  
 
A female of child bearing potential is defined as: 
 A sexually mature woman (i.e. any woman who has ever experienced menstrual 
bleeding) 
AND 
 Who has not undergone a hysterectomy or who has not been postmenopausal for at 
least 24 consecutive months (i.e. Who has had menses at any time within the 
preceding 24 consecutive months) 
 
All males must answer this question 
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Site ID:                       Screening ID:                                                      Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 4 of 8 
 
SECTION C: Assessment of breastfeeding FEMALE patients only  
1. Is the patient currently breastfeeding?  Yes                  No 
 
If YES the patient is ineligible for participation in AVURT. Please proceed directly to section F and 
complete 
If NO please proceed to section D 
SECTION D: Inclusion Criteria 
 
The following criteria MUST all be answered YES for the patient to be included in the 
trial: 
Yes No 
1 At least one chronic venous leg ulcer - where chronic venous leg ulceration is 
defined as any break in the skin which has either:  
 
a) been present for more than six weeks, or  
b) occurred in a person with a history of venous leg ulceration. Ulcers will be 
considered purely venous if clinically no other aetiology was suspected. For this the 
ulcer must be venous in appearance (i.e. moist, shallow, of an irregular shape) and 
lie wholly or partially within the gaiter region of the leg. If the patient has more than 
one ulcer we will choose the largest ulcer as the ‘index’ lesion for purposes of the 
analysis.  
 
  
2   
Ulcer area greater than 1cm2  
 
  
3 Have had an ankle brachial pressure index (ABPI) ≥ 0.8 taken within the previous 
three months or, where ABPI is incompressible, have had PAD excluded in another 
form of assessment such as including peripheral pulse examination / toe pressure / 
duplex ultrasound in combination with clinical judgement to be used to exclude PAD  
  
4 Aged greater than or equal to 18 years (no upper age limit)   
5 Informed consent   
6 Ulcer duration greater than 6 weeks or prior history of venous ulceration   
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Site ID:                        Screening ID:                                                  Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 5 of 8 
SECTION E: Exclusion Criteria 
 
The following criteria MUST all be answered NO for the patient to be included 
in the trial: 
Yes No 
1 Unable to provide consent    
2 Unwilling to provide consent   
3 Foot (below the ankle) ulcer   
4 A leg ulcer of non-venous aetiology (e.g. Arterial)   
5 Ankle-brachial pressure index (ABPI) <0.8 or, where ABPI is not 
compressible, PAD cannot be excluded by other assessments 
  
6 Regular concomitant aspirin   
7 Previous intolerance of aspirin/contraindication to aspirin (decision made 
according to the prescribers’ clinical judgement) 
  
8 Is the patient on any prohibited medication: Oral anticoagulants including 
coumarins (warfarin & acenocoumarol) and phenindione, dabigatran, 
rivaroxaban and apixaban, heparin, clopidogrel, dipyridamole, probenecid, 
sulfinpyrazone & iloprost 
  
9 Known lactose intolerance.   
10 Currently participating in another study evaluating leg ulcer therapies.   
11 Another reason that excluded them from participating within this trial (decision 
made according to the nurses’ or prescribers’ clinical judgement)* 
  
12 Previously been recruited in to this trial.   
 
*Contraindications to Aspirin as listed on the Aspirin SmPC i.e.  Aspirin should not be taken by patients with 
the following conditions: 
• Known hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. 
certain asthma patients who may suffer an attack or faint and certain patients who may suffer from 
bronchospasm, rhinitis and urticaria) and to any of the excipients; 
• Nasal polyps associated with asthma (high risk of severe sensitivity reactions). 
• Active or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage or other kinds of 
bleeding such as cerebrovascular haemorrhage or a past history of ulceration or dyspepsia. 
•Haemorrhagic diathesis; coagulation disorders such as Haemophilia and thrombocytopenia 
• Patients who are suffering from gout  
• Severe hepatic impairment 
• Severe renal impairment 
 
SECTION F: Eligibility  
1. Are all the inclusion criteria answered YES (section D)?  Yes              No  
 
2. Are all the exclusion criteria answered NO (section E)?   Yes              No 
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Site ID:                         Screening ID:                                                  Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 6 of 8 
 
3. Does the participant meet the inclusion criteria in sections B and C    Yes              No 
Patient status (please select only one box in this section) 
The patient is eligible and will be included in AVURT                 please complete all of section G 
The patient is not eligible to be included in AVURT                 please complete section G1 and G2  
then proceed to section H 
The patient is eligible but is to be excluded (state why below)               please complete section G1 
and G2 then proceed to section H 
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Site ID:                       Screening ID:                                                  Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 7 of 8 
SECTION G: Eligibility and medic assessment signoff  
1.  
 
2. Form completed by: 
Signature of staff member performing eligibility 
assessment  
 
Please print name  
Date   
If ineligible, go to Section H and do not complete question G3 below 
 
 
 
 
3. Confirmation by doctor assessor  
 
 By patient By Nurse 
Consent Form has been signed and dated 
(please tick) 
  
 Yes No* 
Confirmation AVURT Screening  satisfactory 
 
  
*If no please specify reasons  
 
 
 
Baseline Medication Questionnaire checked to ensure inclusion in 
AVURT study is not contraindicated 
  
 
*If no please specify reasons  
 
 
 
 
 
Please now pass this form to the named doctor 
assessor (stated on the delegation log) for their 
assessment and counter signature, to be 
completed below, to ensure GCP ce complian
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Site ID:                       Screening ID:                                                  Date DD/MM/YY         
 
 
 
 
AVURT Screening 
Version 1.1 Final 26.05.15 
Page 8 of 8 
Signature of doctor assessor   
Please print name  
Date (DD/MM/YY)  
If the patient is eligible for inclusion in AVURT proceed to randomisation 
 
 
Instructions to the doctor assessor: 
 
- sign the AVURT prescription  and fax to St George’s pharmacy * 
- photocopy the prescription and file in patient notes 
- Ensure the original signed prescription is posted to the Sponsor Pharmacy to facilitate 
release of AVURT study medication to the patient 
*NB All AVURT prescribers must be listed on the delegation log copy held with St George’s 
Pharmacy with a sample signature 
 
SECTION H: If patient is not to proceed to AVURT randomisation 
- retain this form and return to York trials Unit following the procedure in the AVURT trial file 
 
If the individual(s) completing this screening form has any further comments regarding this 
screening visit please enter them here: 
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Appendix 7 Baseline case report form
Site ID:                         Screening ID:                                                    Date   (DD/MM/YY)        
  
AVURT B/L Q 
Version 2.1 Final 10.6.15 
Page 1 of 8 
 
 
AVURT 
 
Aspirin for Venous Ulcers: Randomised Trial  
 
Baseline Questionnaire 
For Study Investigator Completion 
Before completing this form please ensure that the patient has 
signed the consent form indicating their willingness to take part in 
the trial 
I am confident that this information is accurate and complete and I can confirm that the study is being 
conducted according to protocol and any subsequent amendments and that consent was obtained prior to 
study entry. Please sign this after the CRF has been completed in full 
 
 
 
     Signed__________________________________ (Site Principal Investigator) 
   
     Print____________________________________ 
 
     Date (DD.MM.YY)_________________________ 
 
 
 
When completed please fax to York Trials Unit, fax no: 
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Site ID:                         Screening ID:                                                    Date   (DD/MM/YY)        
  
AVURT B/L Q 
Version 2.1 Final 10.6.15 
Page 2 of 8 
 
 
Instructions for this questionnaire 
 
 
This baseline CRF may be completed by the principal investigator or a delegated member of staff 
listed on the AVURT Delegation Log.  
Please complete all sections of this questionnaire putting a cross where applicable, and sign off.  
Please also fill in the Baseline Medication CRF in conjunction with this questionnaire  
 
If you have any questions about completing this questionnaire, please contact a member of the 
York Trials Unit team, whose details you will find in the AVURT site information file.  
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Site ID:                         Screening ID:                                                    Date   (DD/MM/YY)        
  
AVURT B/L Q 
Version 2.1 Final 10.6.15 
Page 3 of 8 
 
 
 
LEG ULCER INFORMATION 
 
The reference leg is the leg with the largest ulcer. 
 
1. Please indicate the leg on which the largest eligible ulcer (the reference ulcer ) is located 
(this is called the reference leg) 
                      Left                  Right 
 
2. ABPI of the reference leg           .   date measured   _____________ 
 
           Unable to take ABPI of the reference leg  
 
 
3. How long is it approximately since the patient developed their FIRST leg ulcer? 
                                                                                                                                                                Years                months             weeks 
 
 
 
4. Total number of ulcers on the reference leg  
              
                                                        
5. Duration approximately of the reference ulcer? 
                                                                                                Years                months             weeks 
 
 
 
6. Total number* of ulcer episodes on reference leg including the reference ulcer  
 
 
*this includes all ulcers that the patient has ever had on the reference leg, both in the past 
and currently 
 
 
 
MOBILITY  
 
7. Mobility (please cross one box only) 
                                                                          Patient walks freely 
                                                                          Patient walks with difficulty 
                                                                          Patient is immobile  
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8. Ankle mobility of reference leg (please cross one box only) 
 
                                                            Patient has full range of ankle motion 
                                                            Patient has reduced range of ankle motion  
                                                            Patient's ankle is fixed 
 
 
DIABETES 
 
9. Does the patient have Type I diabetes     Yes             No  
 
 
10. Does the patient have Type II diabetes      Yes                No 
 
COMPRESSION AND DRESSINGS 
11. What type of compression bandaging does the patient have administered? 
If no bandage, please record ‘no bandage’ under ‘other ‘ below. 
 
Compression bandaging Select one 
Four layer  
3 layer  
3 layer reduced compression  
Reduced compression  
2 layer hosiery (aiming to deliver high 
compression) 
 
Reduced compression hosiery  
Other (please state) 
 
 
11a. What level of ankle pressure (mm Hg) compression is aimed for 
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12. What is the primary dressing (that is in contact with the ulcer)? Select one in the table below:  
If no dressing, please record ‘no dressing’ under ‘other ‘ below. 
 
          
Primary dressing Select one 
Silver-containing  
Iodine containing  
Honey-containing  
Alginate  
Hydrogel  
Soft polymer  
Hydrocolloid  
Foam  
Basic wound contact (absorbent dressing/low 
adherence dressing) 
 
Film  
Other antimicrobial dressing (please state) 
 
Other (please state) 
 
 
HEIGHT AND WEIGHT  
13. Patient height :    Feet              Inches                .                 or            cm                         .  
 
14. Patient weight :   Stones                     pounds                    .         
 or            kilograms                             .  
 
LEG ULCER INFORMATION  
15.  Please confirm you have taken a digital photograph of the reference ulcer (largest eligible 
ulcer) on the reference leg.    Yes            No                                
16. Please confirm you have made a tracing of reference ulcer      Yes                 No 
17.  Size of reference                                                                                .               cm2              
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18. Please draw all leg ulcers on the diagrams below. Clearly indicate the reference ulcer location
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VISUAL ANALOGUE SCORE  
19. What is the patients ulcer related pain over the previous 24 hours  
 
 
20. Confirm the baseline medication questionnaire has been completed Yes           No  
 
21. Which of these best describes the participant’s ethnic group? Please tick one box only 
 
 
White 
 
 
Mixed 
 
Asian or Asian 
British 
 
Black or Black 
British 
 
Chinese, 
Japanese or 
other 
 
White British  
 
White Irish  
 
White,  other 
European       
 
Any other White 
background*  
 
White and Black 
Caribbean            
 
White and Black 
African        
 
White and Asian  
 
Any other mixed 
background*       
 
 
Indian             
 
Pakistani  
 
Bangladeshi  
 
Any other Asian 
background*   
 
Black Caribbean  
 
Black African        
 
Any other Black 
background*        
 
Chinese  
 
Japanese  
 
Other *   
If other please specify: 
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_____________________________________________________         
Name of person completing form (please print)                                       
 
 
_____________________________________________________              _________________________ 
Signature of person completing form                                            Date (DD/MM/YY) 
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Appendix 8 Procedure for taking photographs
                 
   AVURT – Trial Procedure                                                                       
  
Version 1.0, 19 May 2015 
York Trials Unit 
      
Subject: Digital Photography Procedure 
When to take photographs  
Photographs of the reference ulcer should be taken every week.   (If patients are seen 
fortnightly, then a photograph should be taken fortnightly.)  Also, please take a 
photograph of the reference ulcer site when the reference ulcer is first reported as 
healed, one week later where possible, and a photo 2 weeks later after the first 
report of healing.  The photo taken 2 weeks after the first report of healing is important 
as it will be used to confirm whether the ulcer has healed or broken down. 
The Camera 
Please use the camera supplied for the trial, Nikon Coolpix L31.  “All cameras have been 
calibrated so they are standardised to the same specification – please do not change any 
of these settings. All cameras have been calibrated to the same specification as follows”: 1 
Scene auto selector (the icon with the word ‘Scene’ and image of a heart.  This will be 
displayed on screen when you turn the camera on.) In this mode “the camera responds to 
the shooting conditions at the time and controls the majority of camera settings.” 1 The 
flash is set to automatic.  To use the camera please follow the instructions supplied with 
the camera.  
Taking the photograph 
1. Ensure that the ulcer and surrounding area are cleaned thoroughly before taking 
the photograph. 
 
2. Try to reduce glare and shadow2. 
 
3. Reference target card – Place reference target card in image.  Every digital 
photograph must include the reference target card, which includes a centimetre 
measuring scale. The patient’s trial number, site id and date must always be 
clearly written on the reference target card.  [There may be a two digit id already 
pre-printed on the target card, if this number is not your site id, please cross it out 
and write the correct site ID on the card].  During follow-up please include the week 
number on the card.  To enable us so to distinguish week number from site ID, 
please use the prefix ‘wk’, for example, wk 1, wk 2, etc.  Please make sure that the 
reference target card is included in the photograph otherwise the photograph 
cannot be used.  
 
4. Hold the camera  20 cm, (8 inches),  above the ulcer site (at this distance the 
reference target card should be legible on screen) and at “90o above the centre 
of wound”2 – not at an angle.  Please do not use zoom function. “In the case 
of circumferential wounds additional adjacent photographs may be required.  Every 
reasonable effort must be made to take all consecutive photographs from the same 
viewpoint and distance,”1 and using the same trial camera.    
 
5. Ensure that the ulcer is in the centre of the screen.    
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   AVURT – Trial Procedure                                                                       
  
Version 1.0, 19 May 2015 
York Trials Unit 
      
“All digital photographs to be kept confidential and secure for the duration of the trial. 
Patient confidentiality will be maintained throughout trial by the use of unique trial 
numbers”.1 
“No film, recording media or data to be manipulated or changed in any way with the 
intention of affecting the results of the trial.”1 
Sending photographs to the YTU 
All photographs should be sent to the York Trials Unit (YTU) at the University of York 
using their electronic Drop Off Service.  The photographs should be sent as soon as 
possible after the clinic and no later than a week after the photograph(s) were 
taken. The files/photographs must be encrypted before sending them to the YTU.  To 
access the service please go to   .  Drop offs may 
not exceed 20.0 GB per file, or 20.0 GB total for the entire drop off.  If you are not 
permitted by your site to use this service separate arrangements will be arranged.  
Contact one of the trial managers if this is the case.   “DO NOT COMPRESS PHOTOS.”1  
The memory card should hold all the photos that you need to take for the trial.  Please do 
not delete photographs from the memory card until advised to do so by the YTU. 
Faults with the camera and collection of cameras at the end of the study 
If you camera develops a fault, please report it to the YTU as soon as possible.  Please 
contact
 A replacement camera will be sent to you and we will arrange for the return of 
the old one. 
At the end of the study we will arrange for collection or return of the camera(s). 
 
Procedure adapted from: 
1Ashby RL, Gabe R, Ali S, Saramago P, Chuang L-H, Adderley U, et al. VenUS IV 
(Venous leg Ulcer Study IV) – compression hosiery compared with compression 
bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-
treatment comparison and decision-analytic model. Health Technol Assess 2014;18(57) 
2Bhedi A, Saxena AK, Gadani R, Patel R. Digital photography and transparency –based 
methods for measuring wound surface area. Indian J Surg 75:111–14  
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Appendix 9 Medication diary (form completed
by participants)
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Appendix 10 Data collection forms
(forms completed by health-care professionals)
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Appendix 11 The AVURT flow chart
Screening assessment
• Consent obtained
• Inclusion and exclusion criteria checked
• Ulcer measured to determine size
Randomisation: to placebo or aspirin
IMP to be collected by patient on next visit to clinic or posted direct to 
patient
Eligible patients
Ineligible patients
• Anonymised screening
   data recorded
Baseline assessments
Clinical assessments: digital photograph of reference ulcer and tracing
Record of VAS pain score, current medication, medical history,
standard care administered (if any), demographic data, contact
details for patient and their GP
Weekly assessments for 25 weeks post randomisation
• Healing outcomes: digital photograph of reference ulcer and date 
   taken
• Record of treatment concordance (including, initially, date trial
   treatment commenced), AEs/changes in medical condition, 
   changes to other medication, change in type of dressings used
4–6 weeks post randomisation
In addition to weekly assessments, participants will be asked about
ulcer-related pain (VAS pain score)
25 weeks post randomisation: final assessment of patients whose
leg ulcers have been confirmed as healed on or before week 25, 
or whose leg ulcers are not suspected as healed
In addition to weekly assessments, there will be a grid tracing of
reference ulcer
IMP container and remaining medication returned for all trial
participants
26 weeks post randomisation (only patients whose leg ulcers were
suspected as healed in weeks 24 and/or 25)
Digital photograph taken of wound area
Record of AEs, changes to other medication and change in type of 
standard care administered
(For patients whose leg ulcer was suspected as healed in week 24, 
an assessment is made of digital photograph to confirm healing)
27 weeks post randomisation (only patients whose leg ulcers were
suspected as healed in week 25)
Digital photograph taken of wound area
Record of AEs, changes to other medication and change to standard 
care administered/types of dressings
(Assessment of digital photograph to confirm healing)
Reference ulcer judged as healed
• Participant to continue with trial
   medication
1 week after judged as healed
• Healing outcomes: digital photograph 
   of reference ulcer and date taken
• Treatment concordance
• AEs
• Change to standard care
   administered/types of dressings
2 weeks after judged as healed
• Healing outcomes: digital photograph 
   of reference ulcer and date taken,
   and clinical assessment of photograph
• Treatment concordance
• AEs
• Change to standard care
   administered/types of dressings
Healed
• Participant given
   a card and asked
   to notify the trial
   team if wound
   breaks down
• Discontinue trial
   medication
• Remaining
   medication
   returned to the 
   Research Pharmacy 
   (St George’s  
   University Hospitals 
   NHS Foundation 
   Trust)
Not healed
• Participant
   continues with
   trial medication
   and continues
   in trial
25 weeks post randomisation
• Research nurse telephones patient to
   ask if new ulcer and to collect AE data
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Appendix 12 Ulcer recurrence card
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Appendix 13 Study amendments
Ethics submissions
Amendment 1. Substantial (1). Approval not required.
Amendment 2. Substantial (2) and non-substantial (1). Approved 7 May 2016.
Amendment 3. Non-substantial (2). Approved 4 August 2015.
Amendment 4. Substantial (3). Approval not required.
Amendment 5. Substantial (4). Withdrawn.
Amendment 6. Non-substantial (3). Approved 25 July 2016.
Medicines and Healthcare products Regulatory Agency submissions
Amendment 1. Substantial (1). Approved 8 May 2016.
Amendment 2. Substantial (2) and non-substantial (1). Approval not required.
Amendment 3. Non-substantial (2). Approval not required.
Amendment 4. Substantial (3). Approved 14 December 2015.
Amendment 5. Substantial (4). Approval not required.
Amendment 6. Non-substantial (3). Approval not required.
Non-substantial amendments
Amendment 2: non-substantial (1) was not protocol amendment (protocol version 1.3)
Key changes
Minor changes to correct typographical errors and to make clarifications in protocol – sections: 2. Roles and
Responsibilities, 3. Study Synopsis, 6.1 Study disease, 7.1 Overall design, 8.1 IMPs and non-IMPs used in
the trial, 10. Subject/Patient Recruitment process, 11.1 Informed Consent, 12.1 Screening assessments,
12.2 Treatment procedure, 12.3 Subsequent assessments, 12.5.1 Obtaining, labelling, storing, 12.6.1 Obtaining,
labelling, storing, 12.7.1 Obtaining, labelling, storing, 14.3 Data handling and analysis, 16.4.1 Summary of
baseline data and flow of participants and appendix 3 Study Flow Chart and Table of Study Assessments.
Informed consent form amended to facilitate five-digit screening ID (ICF1.2).
Amendment 3: non-substantial (2) was a protocol amendment (protocol 1.4)
Key changes
Clarification of management of patients experiencing AEs/SAEs. Protocol amended to state that patients
who develop SAEs (and not AEs) to aspirin (or placebo) will be withdrawn from study treatments.
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Changes to sections 2. Roles and Responsibilities, 3. Study Synopsis, 6.2 Investigational Medicinal Product
(IMP), 6.5 Assessment & management of potential risk, 8. IMP Dosage regimen and rationale, 11.3
Prescribing & Dispensing IMP, 11.6 Discontinuation/withdrawal of participants and stopping rules and
12.1 Screening assessments.
Amendment 6: non-substantial (3) was a protocol amendment (protocol 1.5)
Section 5. Statement to include that unpublished as well as published studies would be included in
meta-analysis.
Substantial amendments
Amendment 1: substantial amendment 1 (Medicines and Healthcare products Regulatory
Agency) was not a protocol amendment
Simplified IMP Dossier (v2) required adjustment to IMP capsule target weight range.
Amendment 2: substantial amendment 2 (ethics) dated was not a protocol amendment
Two new recruiting sites (Dundee and Lanarkshire) and a change of principal investigator in Bradford.
Amendment 4: substantial amendment 3 (Medicines and Healthcare products
Regulatory Agency) was not a protocol amendment
Change to the expiry date of the IMP following stability information from Sharp Clinical Services
(UK) Limited.
Amendment 5: substantial amendment 4 (ethics) was not a protocol amendment
Change to principal investigator at Wakefield site. Application withdrawn as trial recruitment was stopped.
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Appendix 14 Accumulative recruitment over time
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